Document_and_Entity_Informatio
Document and Entity Information | 9 Months Ended |
Sep. 30, 2014 | |
Document and Entity Information [Line Items] | ' |
Entity Registrant Name | 'GenOn Energy, Inc. |
Entity Central Index Key | '0001126294 |
Current Fiscal Year End Date | '--12-31 |
Entity Filer Category | 'Non-accelerated Filer |
Document Type | '10-Q |
Document Period End Date | 30-Sep-14 |
Document Fiscal Year Focus | '2014 |
Document Fiscal Period Focus | 'Q3 |
Amendment Flag | 'false |
Entity Common Stock, Shares Outstanding | 1 |
Entity Well-known Seasoned Issuer | 'No |
Entity Voluntary Filers | 'Yes |
Entity Current Reporting Status | 'Yes |
GenOn Americas Generation | ' |
Document and Entity Information [Line Items] | ' |
Entity Registrant Name | 'GenOn Americas Generation, LCC |
Entity Central Index Key | '0001140761 |
Current Fiscal Year End Date | '--12-31 |
Entity Filer Category | 'Non-accelerated Filer |
Document Fiscal Year Focus | '2014 |
Document Fiscal Period Focus | 'Q3 |
Entity Common Stock, Shares Outstanding | 0 |
Entity Well-known Seasoned Issuer | 'No |
Entity Voluntary Filers | 'Yes |
Entity Current Reporting Status | 'Yes |
GenOn Mid-Atlantic | ' |
Document and Entity Information [Line Items] | ' |
Entity Registrant Name | 'GenOn Mid-Atlantic, LLC |
Entity Central Index Key | '0001138258 |
Current Fiscal Year End Date | '--12-31 |
Entity Filer Category | 'Non-accelerated Filer |
Document Fiscal Year Focus | '2014 |
Document Fiscal Period Focus | 'Q3 |
Entity Common Stock, Shares Outstanding | 0 |
Entity Well-known Seasoned Issuer | 'No |
Entity Voluntary Filers | 'Yes |
Entity Current Reporting Status | 'Yes |
CONDENSED_CONSOLIDATED_STATEME
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Operating Revenues | ' | ' | ' | ' |
Total operating revenues | $709 | $811 | $2,317 | $1,966 |
Operating Costs and Expenses | ' | ' | ' | ' |
Depreciation and amortization | 52 | 70 | 172 | 207 |
Impairment of Long-Lived Assets to be Disposed of | 60 | 0 | 60 | 0 |
Acquisition-related transaction and integration costs | 1 | 13 | 3 | 54 |
Total operating costs and expenses | 617 | 661 | 2,140 | 1,874 |
Gain (loss) on sale of assets | 0 | 0 | -6 | 0 |
Operating Income/(Loss) | 92 | 150 | 171 | 92 |
Other Income/(Expense) | ' | ' | ' | ' |
Other income/(expense), net | 2 | 2 | 4 | 4 |
Gains (Losses) on Extinguishment of Debt | 0 | 0 | 0 | -11 |
Total other income (expense), net | -46 | -49 | -145 | -161 |
Income/(Loss) Before Income Taxes | 46 | 101 | 26 | -69 |
Income tax expense/(benefit) | 0 | 0 | 2 | -6 |
Net Income/(Loss) | 46 | 101 | 24 | -63 |
GenOn Americas Generation | ' | ' | ' | ' |
Operating Revenues | ' | ' | ' | ' |
Total operating revenues | 642 | 769 | 2,233 | 1,939 |
Operating Costs and Expenses | ' | ' | ' | ' |
Depreciation and amortization | 21 | 26 | 70 | 79 |
Total operating costs and expenses | 576 | 680 | 2,073 | 1,860 |
Gain (loss) on sale of assets | 0 | 0 | -6 | 0 |
Operating Income/(Loss) | 66 | 89 | 154 | 79 |
Other Income/(Expense) | ' | ' | ' | ' |
Other income/(expense), net | 0 | 0 | 0 | 0 |
Total other income (expense), net | -19 | -18 | -56 | -54 |
Income/(Loss) Before Income Taxes | 47 | 71 | 98 | 25 |
Income tax expense/(benefit) | 0 | 0 | 0 | 0 |
Net Income/(Loss) | 47 | 71 | 98 | 25 |
GenOn Mid-Atlantic | ' | ' | ' | ' |
Operating Revenues | ' | ' | ' | ' |
Total operating revenues | 245 | 297 | 768 | 638 |
Operating Costs and Expenses | ' | ' | ' | ' |
Depreciation and amortization | 18 | 22 | 61 | 60 |
Total operating costs and expenses | 200 | 213 | 673 | 569 |
Operating Income/(Loss) | 45 | 84 | 95 | 69 |
Other Income/(Expense) | ' | ' | ' | ' |
Total other income (expense), net | -1 | -2 | -4 | -4 |
Income/(Loss) Before Income Taxes | 44 | 82 | 91 | 65 |
Income tax expense/(benefit) | 0 | 0 | 0 | 0 |
Net Income/(Loss) | 44 | 82 | 91 | 65 |
Non-affiliate | ' | ' | ' | ' |
Operating Revenues | ' | ' | ' | ' |
Total operating revenues | 713 | 794 | 2,300 | 1,934 |
Operating Costs and Expenses | ' | ' | ' | ' |
Cost of operations | 385 | 445 | 1,388 | 1,317 |
Selling, general and administrative | 19 | 30 | 60 | 83 |
Other Income/(Expense) | ' | ' | ' | ' |
Interest expense | -46 | 48 | -140 | 145 |
Non-affiliate | GenOn Americas Generation | ' | ' | ' | ' |
Operating Revenues | ' | ' | ' | ' |
Total operating revenues | 667 | 769 | 2,123 | 1,834 |
Operating Costs and Expenses | ' | ' | ' | ' |
Cost of operations | 198 | 300 | 753 | 679 |
Selling, general and administrative | 2 | 6 | 7 | 8 |
Other Income/(Expense) | ' | ' | ' | ' |
Interest expense | -17 | 16 | -50 | 49 |
Non-affiliate | GenOn Mid-Atlantic | ' | ' | ' | ' |
Operating Revenues | ' | ' | ' | ' |
Total operating revenues | 46 | 19 | -110 | 25 |
Operating Costs and Expenses | ' | ' | ' | ' |
Cost of operations | 141 | 64 | 535 | 216 |
Other Income/(Expense) | ' | ' | ' | ' |
Interest expense | ' | 1 | 1 | 1 |
Affiliate | ' | ' | ' | ' |
Operating Revenues | ' | ' | ' | ' |
Total operating revenues | -4 | 17 | 17 | 32 |
Operating Costs and Expenses | ' | ' | ' | ' |
Cost of operations | 67 | 66 | 358 | 139 |
Selling, general and administrative | 33 | 37 | 99 | 74 |
Other Income/(Expense) | ' | ' | ' | ' |
Interest expense | -2 | 3 | -9 | 9 |
Affiliate | GenOn Americas Generation | ' | ' | ' | ' |
Operating Revenues | ' | ' | ' | ' |
Total operating revenues | -25 | 0 | 110 | 105 |
Operating Costs and Expenses | ' | ' | ' | ' |
Cost of operations | 335 | 333 | 1,181 | 1,037 |
Selling, general and administrative | 20 | 15 | 62 | 57 |
Other Income/(Expense) | ' | ' | ' | ' |
Interest expense | -2 | 2 | -6 | 5 |
Affiliate | GenOn Mid-Atlantic | ' | ' | ' | ' |
Operating Revenues | ' | ' | ' | ' |
Total operating revenues | 199 | 278 | 878 | 613 |
Operating Costs and Expenses | ' | ' | ' | ' |
Cost of operations | 25 | 112 | 26 | 245 |
Selling, general and administrative | 16 | 15 | 51 | 48 |
Other Income/(Expense) | ' | ' | ' | ' |
Interest expense | ($1) | $1 | $3 | $3 |
CONDENSED_CONSOLIDATED_STATEME1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Net income/(loss) | $46 | $101 | $24 | ($63) |
Other comprehensive income net of reclassifications, net of tax of $0: | ' | ' | ' | ' |
Unrealized gain/(loss) on derivatives | 0 | -18 | 0 | -1 |
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax | -5 | 0 | 3 | 30 |
Other comprehensive income/(loss) | -5 | -18 | 3 | 29 |
Comprehensive income/(loss) | $41 | $83 | $27 | ($34) |
CONDENSED_CONSOLIDATED_STATEME2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) Parenthetical (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent | $0 | $0 | $0 | $0 |
CONDENSED_CONSOLIDATED_BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
In Millions, unless otherwise specified | ||
Current Assets | ' | ' |
Cash and cash equivalents | $968 | $760 |
Funds deposited by counterparties | 0 | 56 |
Accounts receivable — trade | 105 | 178 |
Inventory | 424 | 443 |
Cash collateral paid in support of energy risk management activities | 135 | 62 |
Disposal Group, Including Discontinued Operation, Other Assets, Current | 17 | 17 |
Prepayments and other current assets | 154 | 177 |
Total current assets | 2,254 | 2,162 |
Property, Plant and Equipment | ' | ' |
Property, plant and equipment | 3,053 | 3,176 |
Other Assets | ' | ' |
Intangible assets, net of accumulated amortization | 73 | 65 |
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent | 18 | 0 |
Other non-current assets | 179 | 149 |
Assets, Noncurrent | 433 | 396 |
Total Assets | 5,740 | 5,734 |
Current Liabilities | ' | ' |
Current portion of long-term debt and capital leases | 8 | 5 |
Cash collateral received in support of energy risk management activities | 0 | 56 |
Other Accrued Liabilities, Current | 295 | 266 |
Total current liabilities | 866 | 749 |
Other Liabilities | ' | ' |
Long-term debt and capital leases | 3,117 | 3,128 |
Out-of-market contracts | 988 | 1,045 |
Other non-current liabilities | 380 | 481 |
Total non-current liabilities | 4,533 | 4,672 |
Total Liabilities | 5,399 | 5,421 |
Commitments and Contingencies | ' | ' |
Stockholder's Equity | ' | ' |
Common stock: $0.001 par value, 1 share authorized and issued at June 30, 2013 and December 31, 2012 | 0 | 0 |
Additional paid-in capital | 325 | 325 |
Accumulated deficit | -90 | -114 |
Accumulated other comprehensive income | 106 | 102 |
Total Stockholder's Equity | 341 | 313 |
Total Liabilities and Stockholder's Equity | 5,740 | 5,734 |
GenOn Mid-Atlantic | ' | ' |
Current Assets | ' | ' |
Cash and cash equivalents | 129 | 64 |
Inventory | 145 | 158 |
Prepayments and other current assets | 76 | 81 |
Total current assets | 540 | 693 |
Property, Plant and Equipment | ' | ' |
Property, plant and equipment | 934 | 987 |
Other Assets | ' | ' |
Intangible assets, net of accumulated amortization | 10 | 11 |
Other non-current assets | 78 | 25 |
Assets, Noncurrent | 205 | 192 |
Total Assets | 1,679 | 1,872 |
Current Liabilities | ' | ' |
Current portion of long-term debt and capital leases | 5 | 5 |
Other Accrued Liabilities, Current | 60 | 49 |
Total current liabilities | 199 | 134 |
Other Liabilities | ' | ' |
Long-term debt and capital leases | 1 | 5 |
Out-of-market contracts | 553 | 575 |
Other non-current liabilities | 59 | 71 |
Total non-current liabilities | 631 | 660 |
Total Liabilities | 830 | 794 |
Commitments and Contingencies | ' | ' |
Stockholder's Equity | ' | ' |
Total Liabilities and Stockholder's Equity | 1,679 | 1,872 |
Member's Equity | ' | ' |
Members' interest | 849 | 1,078 |
GenOn Americas Generation | ' | ' |
Current Assets | ' | ' |
Cash and cash equivalents | 126 | 63 |
Accounts receivable — trade | 95 | 151 |
Inventory | 240 | 270 |
Cash collateral paid in support of energy risk management activities | 125 | 50 |
Prepayments and other current assets | 99 | 105 |
Total current assets | 1,763 | 1,484 |
Property, Plant and Equipment | ' | ' |
Property, plant and equipment | 1,095 | 1,194 |
Other Assets | ' | ' |
Intangible assets, net of accumulated amortization | 72 | 64 |
Other non-current assets | 85 | 32 |
Assets, Noncurrent | 350 | 285 |
Total Assets | 3,208 | 2,963 |
Current Liabilities | ' | ' |
Current portion of long-term debt and capital leases | 5 | 5 |
Cash collateral received in support of energy risk management activities | 0 | 56 |
Other Accrued Liabilities, Current | 122 | 93 |
Total current liabilities | 953 | 597 |
Other Liabilities | ' | ' |
Long-term debt and capital leases | 932 | 943 |
Out-of-market contracts | 554 | 575 |
Other non-current liabilities | 105 | 116 |
Total non-current liabilities | 1,684 | 1,675 |
Total Liabilities | 2,637 | 2,272 |
Commitments and Contingencies | ' | ' |
Stockholder's Equity | ' | ' |
Total Liabilities and Stockholder's Equity | 3,208 | 2,963 |
Member's Equity | ' | ' |
Members' interest | 571 | 691 |
Non-affiliate | ' | ' |
Current Assets | ' | ' |
Derivative instruments | 447 | 464 |
Other Assets | ' | ' |
Derivative instruments | 161 | 181 |
Current Liabilities | ' | ' |
Accounts payable | 125 | 187 |
Derivative instruments | 405 | 160 |
Other Liabilities | ' | ' |
Derivative instruments | 48 | 18 |
Non-affiliate | GenOn Mid-Atlantic | ' | ' |
Current Assets | ' | ' |
Accounts receivable — trade | 5 | 4 |
Derivative instruments | 126 | 298 |
Other Assets | ' | ' |
Derivative instruments | 16 | 60 |
Current Liabilities | ' | ' |
Accounts payable | 17 | 16 |
Derivative instruments | 5 | 0 |
Non-affiliate | GenOn Americas Generation | ' | ' |
Current Assets | ' | ' |
Derivative instruments | 447 | 462 |
Other Assets | ' | ' |
Derivative instruments | 161 | 181 |
Current Liabilities | ' | ' |
Accounts payable | 44 | 90 |
Derivative instruments | 405 | 160 |
Other Liabilities | ' | ' |
Derivative instruments | 48 | 18 |
Affiliate | ' | ' |
Current Assets | ' | ' |
Derivative instruments | 4 | 5 |
Other Assets | ' | ' |
Derivative instruments | 2 | 1 |
Current Liabilities | ' | ' |
Accounts payable | 19 | 72 |
Derivative instruments | 14 | 3 |
Affiliate | GenOn Mid-Atlantic | ' | ' |
Current Assets | ' | ' |
Accounts receivable — trade | 0 | 35 |
Derivative instruments | 59 | 53 |
Other Assets | ' | ' |
Derivative instruments | 101 | 96 |
Current Liabilities | ' | ' |
Accounts payable | 8 | 0 |
Derivative instruments | 104 | 64 |
Other Liabilities | ' | ' |
Derivative instruments | 18 | 9 |
Affiliate | GenOn Americas Generation | ' | ' |
Current Assets | ' | ' |
Notes Receivable, Related Parties, Current | 331 | 299 |
Derivative instruments | 300 | 84 |
Other Assets | ' | ' |
Derivative instruments | 32 | 8 |
Current Liabilities | ' | ' |
Accounts payable | 104 | 86 |
Derivative instruments | 273 | 107 |
Other Liabilities | ' | ' |
Derivative instruments | $45 | $23 |
CONDENSED_CONSOLIDATED_BALANCE1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
In Millions, except Share data, unless otherwise specified | ||
Property, plant and equipment, accumulated depreciation | $417 | $248 |
Common stock, par value (in dollars per share) | $0.00 | $0.00 |
Common stock, shares authorized (in shares) | 1 | 1 |
Common stock, shares issued (in shares) | 1 | 1 |
Intangible assets, accumulated amortization | 65 | 34 |
GenOn Americas Generation | ' | ' |
Property, plant and equipment, accumulated depreciation | 162 | 96 |
Intangible assets, accumulated amortization | 63 | 34 |
GenOn Mid-Atlantic | ' | ' |
Property, plant and equipment, accumulated depreciation | 138 | 77 |
Intangible assets, accumulated amortization | $1 | $0 |
CONDENSED_CONSOLIDATED_STATEME3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) | 9 Months Ended | |
In Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 |
Cash Flows from Operating Activities | ' | ' |
Net income/(loss) | $24 | ($63) |
Adjustments to reconcile net income/(loss) to net cash provided by operating activities: | ' | ' |
Depreciation and amortization | 172 | 207 |
Amortization of Financing Costs and Discounts | -43 | -57 |
Amortization of out-of-market contracts and emission allowances | -17 | -33 |
Share-based Compensation | ' | 8 |
Gains Losses on Extinguishment of Debt, Non Cash Portion | ' | -28 |
Loss on sale of asset | 6 | 0 |
Impairment of Long-Lived Assets to be Disposed of | 60 | 0 |
Changes in derivative instruments | 323 | 200 |
Changes in collateral deposits supporting energy risk management activities | 73 | -113 |
Changes in other working capital | -173 | 136 |
Net Cash Provided by Operating Activities | 279 | 483 |
Cash Flows from Investing Activities: | ' | ' |
Proceeds from Sale of Investment Projects | 0 | 175 |
Capital expenditures | -125 | -241 |
Decrease in restricted cash, net | ' | 18 |
Purchase of emission allowances, net of proceeds | 0 | -14 |
Proceeds from sale of assets, net of cash disposed of | 50 | 0 |
Payments for (Proceeds from) Other Investing Activities | 5 | 0 |
Net Cash Used by Investing Activities | -70 | -62 |
Cash Flows from Financing Activities | ' | ' |
Proceeds from issuance of long-term debt | 0 | 110 |
Payments for short and long-term debt | -1 | -578 |
Net Cash Used by Financing Activities | -1 | -468 |
Net Increase/(Decrease) in Cash and Cash Equivalents | 208 | -47 |
Cash and Cash Equivalents at Beginning of Period | 760 | 825 |
Cash and Cash Equivalents at Beginning of Period | 968 | 778 |
GenOn Americas Generation | ' | ' |
Cash Flows from Operating Activities | ' | ' |
Net income/(loss) | 98 | 25 |
Adjustments to reconcile net income/(loss) to net cash provided by operating activities: | ' | ' |
Depreciation and amortization | 70 | 79 |
Amortization of Debt Discount (Premium) | -7 | -6 |
Amortization of out-of-market contracts and emission allowances | 10 | -6 |
Loss on sale of asset | 6 | 5 |
Changes in derivative instruments | 258 | 183 |
Changes in collateral deposits supporting energy risk management activities | 131 | -49 |
Changes in other working capital | 49 | -68 |
Net Cash Provided by Operating Activities | 353 | 261 |
Cash Flows from Investing Activities: | ' | ' |
Capital expenditures | -25 | -44 |
Purchase of emission allowances, net of proceeds | ' | -14 |
Proceeds from sale of assets, net of cash disposed of | 50 | 0 |
Net Cash Used by Investing Activities | -7 | -159 |
Cash Flows from Financing Activities | ' | ' |
Payments for short and long-term debt | ' | -3 |
Net Cash Used by Financing Activities | -283 | -126 |
Net Increase/(Decrease) in Cash and Cash Equivalents | 63 | -24 |
Cash and Cash Equivalents at Beginning of Period | 63 | 148 |
Cash and Cash Equivalents at Beginning of Period | 126 | 124 |
GenOn Mid-Atlantic | ' | ' |
Cash Flows from Operating Activities | ' | ' |
Net income/(loss) | 91 | 65 |
Adjustments to reconcile net income/(loss) to net cash provided by operating activities: | ' | ' |
Depreciation and amortization | 61 | 60 |
Amortization of out-of-market contracts and emission allowances | -12 | -8 |
Loss on sale of asset | ' | 5 |
Changes in derivative instruments | 259 | 181 |
Changes in collateral deposits supporting energy risk management activities | ' | 14 |
Changes in other working capital | -3 | -97 |
Net Cash Provided by Operating Activities | 396 | 192 |
Cash Flows from Investing Activities: | ' | ' |
Capital expenditures | -11 | -38 |
Net Cash Used by Investing Activities | -11 | -38 |
Cash Flows from Financing Activities | ' | ' |
Payments for short and long-term debt | ' | -3 |
Net Cash Used by Financing Activities | -320 | -163 |
Net Increase/(Decrease) in Cash and Cash Equivalents | 65 | -9 |
Cash and Cash Equivalents at Beginning of Period | 64 | 135 |
Cash and Cash Equivalents at Beginning of Period | 129 | 126 |
Affiliate | GenOn Americas Generation | ' | ' |
Cash Flows from Investing Activities: | ' | ' |
Decrease in note receivable — affiliate | -32 | -101 |
Cash Flows from Financing Activities | ' | ' |
Proceeds from Contributions from Affiliates | 37 | 37 |
Distribution Made to Limited Liability Company (LLC) Member, Cash Distributions Paid | -320 | -160 |
Affiliate | GenOn Mid-Atlantic | ' | ' |
Cash Flows from Financing Activities | ' | ' |
Distribution Made to Limited Liability Company (LLC) Member, Cash Distributions Paid | ($320) | ($160) |
Basis_of_Presentation
Basis of Presentation | 9 Months Ended |
Sep. 30, 2014 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' |
Basis of Presentation (GenOn, GenOn Americas Generation, GenOn Mid-Atlantic) | ' |
Basis of Presentation (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | |
GenOn Energy, Inc., a wholly owned subsidiary of NRG, is a wholesale power generator engaged in the ownership and operation of power generation facilities, with approximately 19,583 MW of net electric generating capacity located in the U.S. | |
GenOn Americas Generation is a wholesale power generator with approximately 7,596 MW of net electric generating capacity located, in many cases, near major metropolitan areas. GenOn Americas Generation's electric generating capacity is part of the 19,583 MW of net electric generating capacity of GenOn. | |
GenOn Mid-Atlantic operates and owns or leases 4,683 MW of net electric generating capacity in Maryland near Washington, D.C. GenOn Mid-Atlantic’s electric generating capacity is part of the 7,596 MW of net electric generating capacity of GenOn Americas Generation. GenOn Mid-Atlantic’s generating facilities serve the Eastern PJM markets. | |
GenOn Americas Generation and GenOn Mid-Atlantic are Delaware limited liability companies and indirect wholly owned subsidiaries of GenOn. GenOn Mid-Atlantic is an indirect wholly owned subsidiary of GenOn Americas Generation. | |
The Registrants sell power from their generation portfolio, offer capacity or similar products to retail electric providers and others, and provide Ancillary Services to support system reliability. | |
On December 14, 2012, NRG completed the acquisition of GenOn, referred to herein as the NRG Merger. | |
This is a combined quarterly report of the Registrants for the quarter ended September 30, 2014. The notes to the condensed consolidated financial statements apply to the Registrants as indicated parenthetically next to each corresponding disclosure. The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with the SEC's regulations for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. The following notes should be read in conjunction with the accounting policies and other disclosures as set forth in the notes to the Registrants' financial statements set forth in the Registrants' 2013 Form 10-K. Interim results are not necessarily indicative of results for a full year. | |
In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all material adjustments consisting of normal and recurring accruals necessary to present fairly the Registrants' consolidated financial positions as of September 30, 2014, cash flows for the nine months ended September 30, 2014 and 2013 and the results of operations and comprehensive income/(loss) for the three and nine months ended September 30, 2014 and 2013. | |
Use of Estimates | |
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Certain prior year depreciation amounts have been recast to revise provisional purchase accounting estimates for the NRG Merger. | |
Reclassifications | |
Certain prior year amounts have been reclassified for comparative purposes. The reclassification did not affect results from operations. |
Summary_of_Significant_Account
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2014 | |
Significant Accounting Policies [Abstract] | ' |
Summary of Significant Accounting Policies (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | ' |
Summary of Significant Accounting Policies (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | |
Impairment losses | |
During the three months ended September 30, 2014, GenOn determined that it will pursue mothballing the 463 MW natural gas-fired Osceola facility, in Saint Cloud, Florida. GenOn considered this to be an indicator of impairment and performed an impairment test for these assets under ASC 360, Property, Plant and Equipment. The carrying amount of the assets was lower than the future net cash flows expected to be generated by the assets and as a result, the assets are considered to be impaired. GenOn measured the impairment loss as the difference between the carrying amount and the fair value of the assets. Due to the location of the facility, it was determined that the best indicator of fair value is the market value of the combustion turbines. GenOn recorded an impairment loss of approximately $60 million, which represents the excess of the carrying value over the fair market value. | |
Assets Held for Sale | |
During the three months ended September 30, 2014, GenOn entered into a separate agreement to sell its 50% interest in the Sabine Cogen, L.P. This transaction is expected to close in the fourth quarter of 2014. As a result, GenOn has classified the related assets as "held-for-sale" in the consolidated balance sheet as of September 30, 2014. | |
Recent Accounting Developments | |
ASU 2014-09 - In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), or ASU No. 2014-09. The amendments of ASU No. 2014-09 complete the joint effort between the FASB and the International Accounting Standards Board, or IASB, to develop a common revenue standard for U.S. GAAP and International Financial Reporting Standards, or IFRS, and to improve financial reporting. The guidance in ASU No. 2014-09 provides that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for the goods or services provided and establishes the following steps to be applied by an entity: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies the performance obligation. The guidance of ASU No. 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods therein. Early adoption is not permitted. The Registrants are currently evaluating the impact of the standard on the Registrants' results of operations, cash flows and financial position. | |
ASU 2013-11 - In July 2013, the FASB issued ASU No. 2013-11, Income Taxes (Topic 740) Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, or ASU No. 2013-11. The amendments of ASU No. 2013-11, which were adopted on January 1, 2014, require an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction of a deferred tax asset for a net operating loss, or NOL, a similar tax loss or tax credit carryforward rather than a liability when the uncertain tax position would reduce the NOL or other carryforward under the tax law of the applicable jurisdiction and the entity intends to use the deferred tax asset for that purpose. The adoption of this standard did not impact the Registrants' results of operations or cash flows. |
Fair_Value_of_Financial_Instru
Fair Value of Financial Instruments | 9 Months Ended | |||||||||||||||
Sep. 30, 2014 | ||||||||||||||||
Fair Value Disclosures [Abstract] | ' | |||||||||||||||
Fair Value of Financial Instruments (GenOn, GenOn Americas Generation, GenOn Mid-Atlantic) | ' | |||||||||||||||
Fair Value of Financial Instruments (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | ||||||||||||||||
This footnote should be read in conjunction with the complete description under Note 4, Fair Value of Financial Instruments, to the Registrants' 2013 Form 10-K. | ||||||||||||||||
For cash and cash equivalents, funds deposited by counterparties, accounts receivable, note receivable — affiliate, accounts payable, accrued liabilities, restricted cash, and cash collateral paid and received in support of energy risk management activities, the carrying amount approximates fair value because of the short-term maturity of those instruments and are classified as Level 1 within the fair value hierarchy. | ||||||||||||||||
The estimated carrying amounts and fair values of GenOn and GenOn Americas Generation’s debt are as follows: | ||||||||||||||||
GenOn | ||||||||||||||||
As of September 30, 2014 | As of December 31, 2013 | |||||||||||||||
Carrying Amount | Fair Value | Carrying Amount | Fair Value | |||||||||||||
(In millions) | ||||||||||||||||
Long and short-term debt | $ | 3,117 | $ | 2,828 | $ | 3,120 | $ | 3,058 | ||||||||
The fair value of long and short-term debt that is estimated using reported market prices for instruments that are publicly traded is classified as Level 2 within the fair value hierarchy. | ||||||||||||||||
GenOn Americas Generation | ||||||||||||||||
As of September 30, 2014 | As of December 31, 2013 | |||||||||||||||
Carrying Amount | Fair Value | Carrying Amount | Fair Value | |||||||||||||
(In millions) | ||||||||||||||||
Long and short-term debt | $ | 931 | $ | 786 | $ | 938 | $ | 883 | ||||||||
The fair value of long and short-term debt is estimated using reported market prices for instruments that are publicly traded and is classified as Level 2 within the fair value hierarchy. | ||||||||||||||||
Recurring Fair Value Measurements | ||||||||||||||||
Derivative assets and liabilities are carried at fair market value. Realized and unrealized gains and losses included in earnings that are related to energy derivatives are recorded in operating revenues and cost of operations. | ||||||||||||||||
GenOn | ||||||||||||||||
The following tables present assets and liabilities (including affiliate amounts) measured and recorded at fair value on GenOn’s consolidated balance sheet on a recurring basis and their level within the fair value hierarchy: | ||||||||||||||||
As of September 30, 2014 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 116 | $ | 482 | $ | 16 | $ | 614 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 23 | $ | 408 | $ | 36 | $ | 467 | ||||||||
Other assets (b) | $ | 21 | $ | — | $ | — | $ | 21 | ||||||||
(a) There were no transfers during the three and nine months ended September 30, 2014 between Levels 1 and 2. | ||||||||||||||||
(b) Relates to mutual funds held in a rabbi trust for non-qualified deferred compensation plans for certain key and highly compensated employees. | ||||||||||||||||
As of December 31, 2013 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 141 | $ | 507 | $ | 3 | $ | 651 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 25 | $ | 149 | $ | 7 | $ | 181 | ||||||||
Other assets (b) | $ | 37 | $ | — | $ | — | $ | 37 | ||||||||
(a) There were no transfers during the year ended December 31, 2013 between Levels 1 and 2. | ||||||||||||||||
(b) Relates to mutual funds held in a rabbi trust for non-qualified deferred compensation plans for certain key and highly compensated employees. | ||||||||||||||||
The following tables reconcile, for the three and nine months ended September 30, 2014 and 2013, the beginning and ending balances for derivatives that are recognized at fair value in GenOn's consolidated financial statements at least annually using significant unobservable inputs: | ||||||||||||||||
Fair Value Measurement Using Significant Unobservable Inputs (Level 3) | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
Derivatives (a) | Derivatives (a) | |||||||||||||||
(In millions) | ||||||||||||||||
Beginning balance | $ | (44 | ) | $ | 3 | $ | (4 | ) | $ | 17 | ||||||
Total gains/(losses) included in earnings — realized/unrealized | 1 | 1 | 3 | (15 | ) | |||||||||||
Purchases | 22 | 1 | (19 | ) | 3 | |||||||||||
Transfers into Level 3 (b) | 1 | — | — | — | ||||||||||||
Ending balance | $ | (20 | ) | $ | 5 | $ | (20 | ) | $ | 5 | ||||||
(Losses)/gains for the period included in earnings attributable to the change in unrealized gains or losses relating to assets or liabilities still held as of September 30 | $ | — | $ | — | $ | (1 | ) | $ | 1 | |||||||
(a) Consists of derivative assets and liabilities, net. | ||||||||||||||||
(b) Transfers in/out of level 3 are related to the availability of external broker quotes and are valued as of the end of the reporting period. | ||||||||||||||||
GenOn Americas Generation | ||||||||||||||||
The following tables present assets and liabilities (including affiliate amounts) measured and recorded at fair value on GenOn Americas Generation's consolidated balance sheet on a recurring basis and their level within the fair value hierarchy: | ||||||||||||||||
As of September 30, 2014 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 123 | $ | 786 | $ | 31 | $ | 940 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 47 | $ | 675 | $ | 49 | $ | 771 | ||||||||
(a) There were no transfers during the three and nine months ended September 30, 2014 between Levels 1 and 2. | ||||||||||||||||
As of December 31, 2013 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 153 | $ | 575 | $ | 7 | $ | 735 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 74 | $ | 226 | $ | 8 | $ | 308 | ||||||||
(a) There were no transfers during the year ended December 31, 2013 between Levels 1 and 2. | ||||||||||||||||
The following tables reconcile, for the three and nine months ended September 30, 2014 and 2013, the beginning and ending balances for GenOn Americas Generation's derivatives that are recognized at fair value in the consolidated financial statements at least annually using significant unobservable inputs: | ||||||||||||||||
Fair Value Measurement Using Significant Unobservable Inputs (Level 3) | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
Derivatives (a) | Derivatives (a) | |||||||||||||||
(In millions) | ||||||||||||||||
Beginning balance | $ | (41 | ) | $ | 3 | $ | (1 | ) | $ | 17 | ||||||
Total gains/(losses) included in earnings — realized/unrealized | 1 | — | 1 | (16 | ) | |||||||||||
Purchases | 22 | 1 | (18 | ) | 3 | |||||||||||
Ending balance | $ | (18 | ) | $ | 4 | $ | (18 | ) | $ | 4 | ||||||
Gains/(losses) for the period included in earnings attributable to the change in unrealized gains or losses relating to assets or liabilities still held as of September 30 | $ | 1 | $ | (1 | ) | $ | — | $ | — | |||||||
(a) Consists of derivative assets and liabilities, net. | ||||||||||||||||
GenOn Mid-Atlantic | ||||||||||||||||
The following tables present assets and liabilities (including affiliate amounts) measured and recorded at fair value on GenOn Mid-Atlantic's consolidated balance sheet on a recurring basis and their level within the fair value hierarchy: | ||||||||||||||||
As of September 30, 2014 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 92 | $ | 209 | $ | 1 | $ | 302 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 17 | $ | 91 | $ | 19 | $ | 127 | ||||||||
(a) There were no transfers during the three and nine months ended September 30, 2014 between Levels 1 and 2. | ||||||||||||||||
As of December 31, 2013 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 87 | $ | 420 | $ | — | $ | 507 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 13 | $ | 60 | $ | — | $ | 73 | ||||||||
(a) There were no transfers during the year ended December 31, 2013 between Levels 1 and 2. | ||||||||||||||||
The following tables reconcile, for the three and nine months ended September 30, 2014 and 2013, the beginning and ending balances for GenOn Mid-Atlantic's derivatives that are recognized at fair value in the consolidated financial statements at least annually using significant unobservable inputs: | ||||||||||||||||
Fair Value Measurement Using Significant Unobservable Inputs (Level 3) | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
Derivatives (a) | Derivatives (a) | |||||||||||||||
(In millions) | ||||||||||||||||
Beginning balance | $ | (41 | ) | $ | 2 | $ | — | $ | 7 | |||||||
Total gains/(losses) included in earnings — realized/unrealized | 1 | — | — | (7 | ) | |||||||||||
Purchases | 22 | 1 | (18 | ) | 3 | |||||||||||
Ending balance | $ | (18 | ) | $ | 3 | $ | (18 | ) | $ | 3 | ||||||
Gains for the period included in earnings attributable to the change in unrealized gains or losses relating to assets or liabilities still held as of September 30 | $ | 1 | $ | — | $ | — | $ | 1 | ||||||||
(a) Consists of derivative assets and liabilities, net. | ||||||||||||||||
Derivative Fair Value Measurements | ||||||||||||||||
A portion of the Registrants' contracts are exchange-traded contracts with readily available quoted market prices. A majority of the Registrants' contracts are non-exchange-traded contracts valued using prices provided by external sources, primarily price quotations available through brokers or over-the-counter and on-line exchanges. The remainder of the assets and liabilities represent contracts for which external sources or observable market quotes are not available for the whole term or for certain delivery months. These contracts are valued using various valuation techniques including but not limited to internal models that apply fundamental analysis of the market and corroboration with similar markets. As of September 30, 2014, contracts valued with prices provided by models and other valuation techniques make up 3% of GenOn's derivative assets and 8% of GenOn's derivative liabilities, 3% of GenOn Americas Generation’s derivative assets and 6% of GenOn Americas Generation's derivative liabilities and 0% of GenOn Mid-Atlantic’s derivative assets and 15% of GenOn Mid-Atlantic's derivative liabilities. | ||||||||||||||||
The fair value of each contract is discounted using a risk free interest rate. In addition, the Registrants apply a credit reserve to reflect credit risk which is calculated based on published default probabilities. The Registrants' credit reserves were as follows: | ||||||||||||||||
As of September 30, 2014 | As of December 31, 2013 | |||||||||||||||
(In millions) | ||||||||||||||||
GenOn | $ | 1 | $ | 1 | ||||||||||||
GenOn Americas Generation | 1 | 1 | ||||||||||||||
GenOn Mid-Atlantic | 1 | 3 | ||||||||||||||
Concentration of Credit Risk | ||||||||||||||||
In addition to the credit risk discussion as disclosed in Note 2, Summary of Significant Accounting Policies, to the Registrants' 2013 Form 10-K, the following is a discussion of the concentration of credit risk for the Registrants’ financial instruments. Credit risk relates to the risk of loss resulting from non-performance or non-payment by counterparties pursuant to the terms of their contractual obligations. The Registrants are exposed to counterparty credit risk through various activities including wholesale sales and fuel purchases. | ||||||||||||||||
Counterparty Credit Risk | ||||||||||||||||
The Registrants' counterparty credit risk policies are disclosed in their 2013 Form 10-K. As of September 30, 2014, GenOn's counterparty credit exposure was $269 million and GenOn held no collateral (cash and letters of credit) against those positions, resulting in a net exposure of $269 million. Approximately 78% of GenOn's exposure before collateral is expected to roll off by the end of 2015. As of September 30, 2014, GenOn Americas Generation’s counterparty credit exposure was $262 million and GenOn Americas Generation held no collateral (cash and letters of credit) against those positions, resulting in a net exposure of $262 million. Approximately 79% of GenOn Americas Generation’s exposure before collateral is expected to roll off by the end of 2015. As of September 30, 2014, GenOn Mid-Atlantic’s counterparty credit exposure was $142 million and GenOn Mid-Atlantic held no collateral (cash and letters or credit) against those positions, resulting in a net exposure of $142 million. 100% of GenOn Mid-Atlantic’s exposure before collateral is expected to roll off by the end of 2015. The following tables highlight net counterparty credit exposure by industry sector and by counterparty credit quality. Net counterparty credit exposure is defined as the aggregate net asset position for the Registrants with counterparties where netting is permitted under the enabling agreement and includes all cash flow, mark-to-market, NPNS and non-derivative transactions. The exposure is shown net of collateral held and includes amounts net of receivables or payables. | ||||||||||||||||
GenOn | ||||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Financial institutions | 68 | % | ||||||||||||||
Utilities, energy merchants, marketers and other | 22 | |||||||||||||||
ISOs | 10 | |||||||||||||||
Total as of September 30, 2014 | 100 | % | ||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Investment grade | 97 | % | ||||||||||||||
Non-rated | 3 | |||||||||||||||
Total as of September 30, 2014 | 100 | % | ||||||||||||||
(a) Counterparty credit exposure excludes transportation contracts because of the unavailability of market prices. | ||||||||||||||||
GenOn has counterparty credit risk exposure to certain counterparties, each of which represent more than 10% of the total net exposure discussed above. The aggregate of such counterparties' exposure was $163 million. Changes in hedge positions and market prices will affect credit exposure and counterparty concentration. Given the credit quality, diversification and term of the exposure in the portfolio, GenOn does not anticipate a material impact on its financial position or results of operations from nonperformance by any of its counterparties. | ||||||||||||||||
GenOn Americas Generation | ||||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Financial institutions | 70 | % | ||||||||||||||
Utilities, energy merchants, marketers and other | 20 | |||||||||||||||
ISOs | 10 | |||||||||||||||
Total as of September 30, 2014 | 100 | % | ||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Investment grade | 99 | % | ||||||||||||||
Non-rated | 1 | |||||||||||||||
Total as of September 30, 2014 | 100 | % | ||||||||||||||
(a) Counterparty credit exposure excludes transportation contracts because of the unavailability of market prices. | ||||||||||||||||
GenOn Americas Generation has counterparty credit risk exposure to certain counterparties, each of which represent more than 10% of the total net exposure discussed above. The aggregate of such counterparties' exposure was $163 million. Changes in hedge positions and market prices will affect credit exposure and counterparty concentration. Given the credit quality, diversification and term of the exposure in the portfolio, GenOn Americas Generation does not anticipate a material impact on its financial position or results of operations from nonperformance by any of its counterparties. | ||||||||||||||||
GenOn Mid-Atlantic | ||||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Financial institutions | 100 | % | ||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Investment grade | 100 | % | ||||||||||||||
(a) Counterparty credit exposure excludes transportation contracts because of the unavailability of market prices. | ||||||||||||||||
GenOn Mid-Atlantic has counterparty credit risk exposure to certain counterparties, each of which represent more than 10% of the total net exposure discussed above. The aggregate of such counterparties' exposure was $136 million. Changes in hedge positions and market prices will affect credit exposure and counterparty concentration. Given the credit quality, diversification and term of the exposure in the portfolio, GenOn Mid-Atlantic does not anticipate a material impact on its financial position or results of operations from nonperformance by any of its counterparties. |
Accounting_for_Derivative_Inst
Accounting for Derivative Instruments and Hedging Activities | 9 Months Ended | ||||||||||||||||
Sep. 30, 2014 | |||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | ||||||||||||||||
Accounting for Derivative Instruments and Hedging Activities (GenOn, GenOn Americas Generation, GenOn Mid-Atlantic) | ' | ||||||||||||||||
Accounting for Derivative Instruments and Hedging Activities (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | |||||||||||||||||
This footnote should be read in conjunction with the complete description under Note 5, Accounting for Derivative Instruments and Hedging Activities, to the 2013 Form 10-K. | |||||||||||||||||
Energy-Related Commodities (GenOn) | |||||||||||||||||
As of September 30, 2014, GenOn had energy-related derivative financial instruments extending through 2017. | |||||||||||||||||
Volumetric Underlying Derivative Transactions (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | |||||||||||||||||
The following table summarizes the net notional volume buy/(sell) of the Registrants’ open derivative transactions broken out by commodity, excluding those derivatives that qualified for the NPNS exception as of September 30, 2014 and December 31, 2013. Option contracts are reflected using delta volume. Delta volume equals the notional volume of an option adjusted for the probability that the option will be in-the-money at its expiration date. | |||||||||||||||||
GenOn | GenOn Americas Generation | GenOn Mid-Atlantic | |||||||||||||||
Total Volume | Total Volume | Total Volume | |||||||||||||||
As of September 30, 2014 | As of December 31, 2013 | As of September 30, 2014 | As of December 31, 2013 | As of September 30, 2014 | As of December 31, 2013 | ||||||||||||
Commodity | Units | (In millions) | |||||||||||||||
Coal | Short Ton | 10 | 6 | 7 | 4 | 7 | 4 | ||||||||||
Natural Gas | MMBtu | (47 | ) | -111 | (55 | ) | -113 | (59 | ) | -119 | |||||||
Power | MWh | (38 | ) | -26 | (19 | ) | -14 | (18 | ) | -14 | |||||||
The decrease in the natural gas position was the result of buying back a portion of the gas hedges and replacing them with power hedges, as well as the settlement of positions during the period. | |||||||||||||||||
Fair Value of Derivative Instruments (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | |||||||||||||||||
The following tables summarize the fair value within the derivative instrument valuation on the balance sheet: | |||||||||||||||||
GenOn | |||||||||||||||||
Fair Value | |||||||||||||||||
Derivative Assets | Derivative Liabilities | ||||||||||||||||
30-Sep-14 | 31-Dec-13 | 30-Sep-14 | 31-Dec-13 | ||||||||||||||
(In millions) | |||||||||||||||||
Derivatives Not Designated as Cash Flow Hedges: | |||||||||||||||||
Commodity contracts current | $ | 451 | $ | 469 | $ | 419 | $ | 163 | |||||||||
Commodity contracts long-term | 163 | 182 | 48 | 18 | |||||||||||||
Total Derivatives Not Designated as Cash Flow Hedges | $ | 614 | $ | 651 | $ | 467 | $ | 181 | |||||||||
GenOn Americas Generation | |||||||||||||||||
Fair Value | |||||||||||||||||
Derivative Assets | Derivative Liabilities | ||||||||||||||||
30-Sep-14 | 31-Dec-13 | 30-Sep-14 | 31-Dec-13 | ||||||||||||||
(In millions) | |||||||||||||||||
Derivatives Not Designated as Cash Flow Hedges: | |||||||||||||||||
Commodity contracts current | $ | 747 | $ | 546 | $ | 678 | $ | 267 | |||||||||
Commodity contracts long-term | 193 | 189 | 93 | 41 | |||||||||||||
Total Derivatives Not Designated as Cash Flow Hedges | $ | 940 | $ | 735 | $ | 771 | $ | 308 | |||||||||
GenOn Mid-Atlantic | |||||||||||||||||
Fair Value | |||||||||||||||||
Derivative Assets | Derivative Liabilities | ||||||||||||||||
30-Sep-14 | 31-Dec-13 | 30-Sep-14 | 31-Dec-13 | ||||||||||||||
(In millions) | |||||||||||||||||
Derivatives Not Designated as Cash Flow Hedges: | |||||||||||||||||
Commodity contracts current | $ | 185 | $ | 351 | $ | 109 | $ | 64 | |||||||||
Commodity contracts long-term | 117 | 156 | 18 | 9 | |||||||||||||
Total Derivatives Not Designated as Cash Flow Hedges | $ | 302 | $ | 507 | $ | 127 | $ | 73 | |||||||||
The Registrants have elected to present derivative assets and liabilities on the balance sheet on a trade-by-trade basis and do not offset amounts at the counterparty master agreement level. In addition, collateral received or paid on the Registrants' derivative assets or liabilities are recorded on a separate line item on the balance sheet. The following tables summarize the offsetting of derivatives by counterparty master agreement level and collateral received or paid: | |||||||||||||||||
GenOn | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
September 30, 2014 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 608 | $ | (435 | ) | $ | — | $ | 173 | ||||||||
Derivative assets - affiliate | 6 | (6 | ) | — | — | ||||||||||||
Derivative liabilities | (453 | ) | 435 | 3 | (15 | ) | |||||||||||
Derivative liabilities - affiliate | (14 | ) | 6 | — | (8 | ) | |||||||||||
Total derivative instruments | $ | 147 | $ | — | $ | 3 | $ | 150 | |||||||||
GenOn Americas Generation | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
September 30, 2014 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 608 | $ | (435 | ) | $ | — | $ | 173 | ||||||||
Derivative assets - affiliate | 332 | (318 | ) | — | 14 | ||||||||||||
Derivative liabilities | (453 | ) | 435 | 3 | (15 | ) | |||||||||||
Derivative liabilities - affiliate | (318 | ) | 318 | — | — | ||||||||||||
Total derivative instruments | $ | 169 | $ | — | $ | 3 | $ | 172 | |||||||||
GenOn Mid-Atlantic | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
September 30, 2014 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 142 | $ | (5 | ) | $ | — | $ | 137 | ||||||||
Derivative assets - affiliate | 160 | (122 | ) | — | 38 | ||||||||||||
Derivative liabilities | (5 | ) | 5 | — | — | ||||||||||||
Derivative liabilities - affiliate | (122 | ) | 122 | — | — | ||||||||||||
Total derivative instruments | $ | 175 | $ | — | $ | — | $ | 175 | |||||||||
GenOn | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
December 31, 2013 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 645 | $ | (154 | ) | $ | (56 | ) | $ | 435 | |||||||
Derivative assets - affiliate | 6 | (3 | ) | — | 3 | ||||||||||||
Derivative liabilities | (178 | ) | 154 | — | (24 | ) | |||||||||||
Derivative liabilities - affiliate | (3 | ) | 3 | — | — | ||||||||||||
Total derivative instruments | $ | 470 | $ | — | $ | (56 | ) | $ | 414 | ||||||||
GenOn Americas Generation | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
December 31, 2013 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 643 | $ | (154 | ) | $ | (56 | ) | $ | 433 | |||||||
Derivative assets - affiliate | 92 | (92 | ) | — | — | ||||||||||||
Derivative liabilities | (178 | ) | 154 | — | (24 | ) | |||||||||||
Derivative liabilities - affiliate | (130 | ) | 92 | — | (38 | ) | |||||||||||
Total derivative instruments | $ | 427 | $ | — | $ | (56 | ) | $ | 371 | ||||||||
GenOn Mid-Atlantic | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
December 31, 2013 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 358 | $ | — | $ | — | $ | 358 | |||||||||
Derivative assets - affiliate | 149 | (73 | ) | — | 76 | ||||||||||||
Derivative liabilities | — | — | — | — | |||||||||||||
Derivative liabilities - affiliate | (73 | ) | 73 | — | — | ||||||||||||
Total derivative instruments | $ | 434 | $ | — | $ | — | $ | 434 | |||||||||
Accumulated Other Comprehensive Income (GenOn) | |||||||||||||||||
The following table summarizes the effects on GenOn's accumulated OCI balance attributable to cash flow hedge derivatives: | |||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Accumulated OCI balance, beginning of period | $ | — | $ | 18 | $ | — | $ | 1 | |||||||||
Recognized in OCI on interest rate derivatives | — | — | — | 19 | |||||||||||||
Reclassified from accumulated OCI into earnings(a)(b) | — | — | — | (2 | ) | ||||||||||||
Reversal as part of sale to NRG Yield LLC(c) | — | (18 | ) | — | (18 | ) | |||||||||||
Accumulated OCI balance, end of period | $ | — | $ | — | $ | — | $ | — | |||||||||
(a) | Amounts reclassified from accumulated OCI into income and amounts recognized in income from the ineffective portion of cash flow hedges are recorded in interest expense. | ||||||||||||||||
(b) | All of the forecasted transactions (future interest payments) were deemed probable of occurring; therefore, no cash flow hedges were discontinued and no amount was recognized in GenOn’s results of operations as a result of discontinued cash flow hedges. | ||||||||||||||||
(c) | The reversal of accumulated OCI as part of the sale of NRG Marsh Landing to NRG Yield LLC resulted in the recognition of additional paid in capital. | ||||||||||||||||
Impact of Derivative Instruments on the Statements of Operations (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | |||||||||||||||||
Unrealized gains and losses associated with changes in the fair value of derivative instruments not accounted for as cash flow hedges are reflected in current period earnings. | |||||||||||||||||
The following tables summarize the pre-tax effects of economic hedges that have not been designated as cash flow hedges and trading activity on the Registrants’ statements of operations. These amounts are included within operating revenues and cost of operations. | |||||||||||||||||
GenOn | |||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Unrealized mark-to-market results | |||||||||||||||||
Reversal of previously recognized unrealized gains on settled positions related to economic hedges | $ | (59 | ) | $ | (73 | ) | $ | (210 | ) | $ | (270 | ) | |||||
Net unrealized gains/(losses) on open positions related to economic hedges | 57 | 18 | (112 | ) | 56 | ||||||||||||
Total unrealized mark-to-market losses for economic hedging activities | (2 | ) | (55 | ) | (322 | ) | (214 | ) | |||||||||
Reversal of previously recognized unrealized gains on settled positions related to trading activity | — | (1 | ) | (1 | ) | (3 | ) | ||||||||||
Net unrealized (losses)/gains on open positions related to trading activity | — | (1 | ) | — | 1 | ||||||||||||
Total unrealized mark-to-market losses for trading activity | — | (2 | ) | (1 | ) | (2 | ) | ||||||||||
Total unrealized losses | $ | (2 | ) | $ | (57 | ) | $ | (323 | ) | $ | (216 | ) | |||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Revenue from operations — energy commodities | $ | 3 | $ | (48 | ) | $ | (341 | ) | $ | (238 | ) | ||||||
Cost of operations | (5 | ) | (9 | ) | 18 | 22 | |||||||||||
Total impact to statements of operations | $ | (2 | ) | $ | (57 | ) | $ | (323 | ) | $ | (216 | ) | |||||
GenOn Americas Generation | |||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Unrealized mark-to-market results | |||||||||||||||||
Reversal of previously recognized unrealized gains on settled positions related to economic hedges | $ | (65 | ) | $ | (69 | ) | $ | (201 | ) | $ | (218 | ) | |||||
Net unrealized gains/(losses) on open positions related to economic hedges | 30 | 11 | (55 | ) | 37 | ||||||||||||
Total unrealized mark-to-market losses for economic hedging activities | (35 | ) | (58 | ) | (256 | ) | (181 | ) | |||||||||
Reversal of previously recognized unrealized gains on settled positions related to trading activity | — | (1 | ) | (1 | ) | (3 | ) | ||||||||||
Net unrealized (losses)/gains on open positions related to trading activity | — | (1 | ) | — | 1 | ||||||||||||
Total unrealized mark-to-market losses for trading activity | — | (2 | ) | (1 | ) | (2 | ) | ||||||||||
Total unrealized losses | $ | (35 | ) | $ | (60 | ) | $ | (257 | ) | $ | (183 | ) | |||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Revenue from operations — energy commodities | $ | (27 | ) | $ | (52 | ) | $ | (266 | ) | $ | (205 | ) | |||||
Cost of operations | (8 | ) | (8 | ) | 9 | 22 | |||||||||||
Total impact to statements of operations | $ | (35 | ) | $ | (60 | ) | $ | (257 | ) | $ | (183 | ) | |||||
GenOn Mid-Atlantic | |||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Unrealized mark-to-market results | |||||||||||||||||
Reversal of previously recognized unrealized gains on settled positions related to economic hedges | $ | (63 | ) | $ | (70 | ) | $ | (203 | ) | $ | (220 | ) | |||||
Net unrealized gains/(losses) on open positions related to economic hedges | 31 | 11 | (54 | ) | 39 | ||||||||||||
Total unrealized losses | $ | (32 | ) | $ | (59 | ) | $ | (257 | ) | $ | (181 | ) | |||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Revenue from operations — energy commodities | $ | (24 | ) | $ | (51 | ) | $ | (267 | ) | $ | (203 | ) | |||||
Cost of operations | (8 | ) | (8 | ) | 10 | 22 | |||||||||||
Total impact to statements of operations | $ | (32 | ) | $ | (59 | ) | $ | (257 | ) | $ | (181 | ) | |||||
Credit Risk Related Contingent Features (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | |||||||||||||||||
Certain of GenOn and GenOn Americas Generation’s hedging agreements contain provisions that require the Registrants to post additional collateral if the counterparty determines that there has been deterioration in credit quality, generally termed "adequate assurance" under the agreements, or require the Registrants to post additional collateral if there were a one notch downgrade in the Registrants’ credit rating. The collateral required for contracts that have adequate assurance clauses that are in net liability positions as of September 30, 2014 was $16 million for GenOn and GenOn Americas Generation. The collateral required for contracts with credit rating contingent features that are in a net liability position as of September 30, 2014, was $1 million for GenOn and GenOn Americas Generation. In addition, GenOn and GenOn Americas Generation are parties to certain marginable agreements under which they have net liability positions, but the counterparties have not called for collateral due, which is approximately $1 million for GenOn and GenOn Americas Generation as of September 30, 2014. As of September 30, 2014, GenOn Mid-Atlantic is not party to certain marginable agreements under which they have net liability positions, but the counterparties have not called for collateral due. | |||||||||||||||||
See Note 3, Fair Value of Financial Instruments, for discussion regarding concentration of credit risk. |
Income_Taxes
Income Taxes | 9 Months Ended | |||||||||||||||
Sep. 30, 2014 | ||||||||||||||||
Income Tax Disclosure [Abstract] | ' | |||||||||||||||
Income Taxes (GenOn, GenOn Americas Generation, GenOn Mid-Atlantic) | ' | |||||||||||||||
Income Taxes (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | ||||||||||||||||
GenOn | ||||||||||||||||
GenOn’s income tax expense/(benefit) consisted of the following: | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
(In millions except otherwise noted) | 2014 | 2013 | 2014 | 2013 | ||||||||||||
Income/(loss) before income taxes | $ | 46 | $ | 101 | $ | 26 | $ | (69 | ) | |||||||
Income tax expense/(benefit) | — | — | 2 | (6 | ) | |||||||||||
Effective tax rate | — | % | — | % | 7.7 | % | 8.7 | % | ||||||||
GenOn | ||||||||||||||||
For the three months ended September 30, 2014, GenOn's overall effective tax rate was lower than the statutory rate of 35% primarily due to a change in the valuation allowance. For the nine months ended September 30, 2014, GenOn's overall effective tax rate was different than the statutory rate of 35% primarily due to a change in the valuation allowance and the impact of state income taxes. For the three and nine months ended September 30, 2013, GenOn's overall effective tax rate was lower than the statutory rate of 35% primarily due to a change in the valuation allowance. Through September 30, 2014, GenOn recorded income tax expense relating to state income tax payments. | ||||||||||||||||
GenOn Americas Generation | ||||||||||||||||
GenOn Americas Generation's allocated income taxes resulting from its operations for the three and nine months ended September 30, 2014 and 2013 were $0. For the nine months ended September 30, 2014, the income tax expense relates to state income tax payments attributable to its parent, GenOn. For the nine months ended September 30, 2013, the income tax benefit relates to changes in reserves for uncertain tax benefits attributable to its parent, GenOn. GenOn Americas Generation's pro forma income taxes resulting from its operations for the three and nine months ended September 30, 2014 and 2013 are $0 due to the valuation allowance recorded on its stand-alone financial results. | ||||||||||||||||
GenOn Mid-Atlantic | ||||||||||||||||
GenOn Mid-Atlantic’s allocated income taxes resulting from its operations are $0 for the three and nine months ended September 30, 2014 and 2013. For the nine months ended September 30, 2014, income tax expense relates to state income tax payments attributable to its parent, GenOn. For the nine months ended September 30, 2013, the income tax benefit relates to changes in reserves for uncertain tax benefits attributable to its parent, GenOn. The pro forma income tax provision attributable to income before taxes is a tax expense of $16 million and $36 million during the three months ended September 30, 2014 and 2013, respectively. The pro forma income tax provision attributable to income before taxes is a tax expense of $33 million and $32 million during the nine months ended September 30, 2014 and 2013, respectively. The balance of GenOn Mid-Atlantic's pro forma deferred income taxes is a net deferred tax asset of $106 million and $141 million as of September 30, 2014 and December 31, 2013, respectively. |
Related_Party_Transactions
Related Party Transactions | 9 Months Ended | |||||||||||||||
Sep. 30, 2014 | ||||||||||||||||
Related Party Transactions [Abstract] | ' | |||||||||||||||
Related Party Transactions (GenOn, GenOn Americas Generaiton, GenOn Mid-Atlantic) | ' | |||||||||||||||
Related Party Transactions (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | ||||||||||||||||
Services Agreement with NRG | ||||||||||||||||
NRG provides GenOn with various management, personnel and other services, which include human resources, regulatory and public affairs, accounting, tax, legal, information systems, treasury, risk management, commercial operations, and asset management, as set forth in its services agreement with NRG, or the Services Agreement. The initial term of the Services Agreement was through December 31, 2013, with an automatic renewal absent a request for termination. The fee charged is determined based on a fixed amount as described in the Services Agreement and was calculated based on historical GenOn expenses prior to the NRG Merger. The annual fees under the Services Agreement are approximately $193 million. NRG charges these fees on a monthly basis, less amounts incurred directly by GenOn. Management has concluded that this method of charging overhead costs is reasonable. For the three and nine months ended September 30, 2014, GenOn recorded costs related to these services of $33 million and $99 million, respectively, as selling, general and administrative — affiliate. For the three and nine months ended September 30, 2013, GenOn recorded costs related to these services of $37 million and $62 million, respectively, as selling, general and administrative — affiliate. | ||||||||||||||||
Under the Services Agreement, NRG also provides GenOn Americas Generation and GenOn Mid-Atlantic with various management, personnel and other services consistent with those set forth in the Services Agreement discussed above between NRG and GenOn. GenOn's costs incurred under the Services Agreement with NRG are allocated to its subsidiaries based on each operating subsidiary's planned operating expenses relative to all operating subsidiaries of GenOn. These allocations and charges are not necessarily indicative of what would have been incurred had GenOn Americas Generation and GenOn Mid-Atlantic been unaffiliated entities. Management has concluded that this method of charging overhead costs is reasonable. | ||||||||||||||||
The following costs were incurred under these arrangements: | ||||||||||||||||
GenOn Americas Generation | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
(In millions) | ||||||||||||||||
Allocated costs: | ||||||||||||||||
Cost of operations — affiliate | $ | — | $ | 2 | $ | 1 | $ | 7 | ||||||||
Selling, general and administrative — affiliate | 20 | 18 | 62 | 57 | ||||||||||||
Total | $ | 20 | $ | 20 | $ | 63 | $ | 64 | ||||||||
GenOn Mid-Atlantic | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
(In millions) | ||||||||||||||||
Allocated costs: | ||||||||||||||||
Cost of operations — affiliate | $ | — | $ | 2 | $ | — | $ | 5 | ||||||||
Selling, general and administrative — affiliate | 17 | 15 | 52 | 48 | ||||||||||||
Total | $ | 17 | $ | 17 | $ | 52 | $ | 53 | ||||||||
Credit Agreement with NRG (GenOn) | ||||||||||||||||
In connection with the closing of the NRG Merger, GenOn and GenOn Americas entered into a secured intercompany revolving credit agreement with NRG. This credit agreement provides for a $500 million revolving credit facility, all of which is available for revolving loans and letters of credit. At September 30, 2014 and December 31, 2013, $219 million and $349 million of letters of credit were issued and outstanding under the NRG credit agreement, of which $151 million and $258 million were issued on behalf of GenOn Americas Generation. At September 30, 2014 and December 31, 2013, no loans were outstanding under this credit agreement. In connection with the execution of the agreement, certain of GenOn's subsidiaries, as guarantors, entered into a guarantee agreement pursuant to which these guarantors guaranteed amounts borrowed and obligations incurred under the credit agreement. The credit agreement has a three year maturity and is payable at maturity, subject to certain exceptions primarily related to asset sales not in the ordinary course of business and borrowings of debt. In addition, the guarantors are restricted from incurring additional liens on their assets. At GenOn's election, the interest rate per year applicable to the loans under the credit agreement will be determined by reference to either (i) the base rate plus 2.50% per year or (ii) the LIBOR rate plus 3.50% per year. In addition, the credit agreement contains customary covenants and events of default. | ||||||||||||||||
Intercompany Cash Management Program (GenOn Americas Generation) | ||||||||||||||||
GenOn Americas Generation and certain of its subsidiaries participate in separate intercompany cash management programs whereby cash balances at GenOn Americas Generation and the respective participating subsidiaries are transferred to central concentration accounts to fund working capital and other needs of the respective participants. The balances under this program are reflected as notes receivable — affiliate or notes payable — affiliate, as appropriate. The notes are due on demand and accrue interest on the net position, which is payable quarterly, at a rate determined by GenOn Energy Holdings, a wholly owned subsidiary of GenOn. At September 30, 2014 and December 31, 2013, GenOn Americas Generation had a net current note receivable from GenOn Energy Holdings of $331 million and $299 million, respectively, related to its intercompany cash management program. For the nine months ended September 30, 2014 and 2013, GenOn Americas Generation earned an insignificant amount of net interest income related to these notes. | ||||||||||||||||
GenOn Mid-Atlantic Distribution (GenOn Americas Generation and GenOn Mid-Atlantic) | ||||||||||||||||
In May 2014, GenOn Mid-Atlantic made a distribution of $320 million to its parent, NRG North America LLC, who in turn made a distribution of $320 million to its parent, GenOn Americas Generation. GenOn Americas Generation subsequently made a distribution to GenOn in the same amount, through its parent companies NRG Americas, Inc. and GenOn Energy Holdings, Inc. |
Commitments_and_Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2014 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Commitments and Contingencies (GenOn, GenOn Americas Generation, GenOn Mid-Atlantic) | ' |
Commitments and Contingencies (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | |
This footnote should be read in conjunction with the complete description under Note 18, Commitments and Contingencies, to the Registrants' 2013 Form 10-K. | |
Contingencies | |
Set forth below is a description of the Registrants’ material legal proceedings. The Registrants believe that they have valid defenses to these legal proceedings and intend to defend them vigorously. The Registrants record reserves for estimated losses from contingencies when information available indicates that a loss is probable and the amount of the loss, or range of loss, can be reasonably estimated. In addition, legal costs are expensed as incurred. Management has assessed each of the following matters based on current information and made a judgment concerning its potential outcome, considering the nature of the claim, the amount and nature of damages sought, and the probability of success. Unless specified below, the Registrants are unable to predict the outcome of these legal proceedings or reasonably estimate the scope or amount of any associated costs and potential liabilities. As additional information becomes available, management adjusts its assessment and estimates of such contingencies accordingly. Because litigation is subject to inherent uncertainties and unfavorable rulings or developments, it is possible that the ultimate resolution of the Registrants’ liabilities and contingencies could be at amounts that are different from currently recorded reserves and that such difference could be material. | |
In addition to the legal proceedings noted below, the Registrants are parties to other litigation or legal proceedings arising in the ordinary course of business. In management's opinion, the disposition of these ordinary course matters will not materially adversely affect the Registrants’ respective consolidated financial position, results of operations, or cash flows. | |
Actions Pursued by MC Asset Recovery (GenOn) | |
With Mirant Corporation's emergence from bankruptcy protection in 2006, certain actions filed by GenOn Energy Holdings and some of its subsidiaries against third parties were transferred to MC Asset Recovery, a wholly owned subsidiary of GenOn Energy Holdings. MC Asset Recovery is governed by a manager who is independent of NRG and GenOn. MC Asset Recovery is a disregarded entity for income tax purposes. Under the remaining action transferred to MC Asset Recovery, MC Asset Recovery seeks to recover damages from Commerzbank AG and various other banks, or the Commerzbank Defendants, for alleged fraudulent transfers that occurred prior to Mirant's bankruptcy proceedings. In December 2010, the U.S. District Court for the Northern District of Texas dismissed MC Asset Recovery's complaint against the Commerzbank Defendants. In January 2011, MC Asset Recovery appealed the District Court's dismissal of its complaint against the Commerzbank Defendants to the U.S. Court of Appeals for the Fifth Circuit. In March 2012, the Court of Appeals reversed the District Court's dismissal and reinstated MC Asset Recovery's amended complaint against the Commerzbank Defendants. If MC Asset Recovery succeeds in obtaining any recoveries from the Commerzbank Defendants, the Commerzbank Defendants have asserted that they will seek to file claims in Mirant's bankruptcy proceedings for the amount of those recoveries. GenOn Energy Holdings would vigorously contest the allowance of any such claims. If the Commerzbank Defendants were to receive an allowed claim as a result of a recovery by MC Asset Recovery on its claims against them, GenOn Energy Holdings would retain from the net amount recovered by MC Asset Recovery an amount equal to the dollar amount of the resulting allowed claim. | |
Pending Natural Gas Litigation (GenOn) | |
GenOn is party to several lawsuits, certain of which are class action lawsuits, in state and federal courts in Kansas, Missouri, Nevada and Wisconsin. These lawsuits were filed in the aftermath of the California energy crisis in 2000 and 2001 and the resulting FERC investigations and relate to alleged conduct to increase natural gas prices in violation of antitrust and similar laws. The lawsuits seek treble or punitive damages, restitution and/or expenses. The lawsuits also name as parties a number of energy companies unaffiliated with NRG. In July 2011, the U.S. District Court for the District of Nevada, which is handling four of the five cases, granted the defendants' motion for summary judgment and dismissed all claims against GenOn in those cases. The plaintiffs appealed to the U.S. Court of Appeals for the Ninth Circuit. The Court of Appeals reversed the decision of the District Court. On August 26, 2013, GenOn along with the other defendants in the lawsuit filed a petition for a writ of certiorari to the U.S. Supreme Court challenging the Court of Appeal's decision. On July 1, 2014, the U.S. Supreme Court granted the petition for a writ of certiorari. On September 18, 2014, GenOn along with its co-defendants filed their Opening Brief with the U.S. Supreme Court. | |
In September 2012, the State of Nevada Supreme Court, which is handling the remaining case, affirmed dismissal by the Eighth Judicial District Court for Clark County, Nevada of all plaintiffs' claims against GenOn. In February 2013, the plaintiffs in the Nevada case filed a petition for a writ of certiorari to the U.S. Supreme Court. In June 2013, the U.S. Supreme Court denied the petition for a writ of certiorari, thereby ending one of the five lawsuits. GenOn has agreed to indemnify CenterPoint against certain losses relating to these lawsuits. | |
Cheswick Class Action Complaint (GenOn) | |
In April 2012, a putative class action lawsuit was filed against GenOn in the Court of Common Pleas of Allegheny County, Pennsylvania alleging that emissions from the Cheswick generating facility have damaged the property of neighboring residents. GenOn disputes these allegations. Plaintiffs have brought nuisance, negligence, trespass and strict liability claims seeking both damages and injunctive relief. Plaintiffs seek to certify a class that consists of people who own property or live within one mile of the plant. In July 2012, GenOn removed the lawsuit to the U.S. District Court for the Western District of Pennsylvania. In October 2012, the court granted GenOn’s motion to dismiss, which Plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. On August 20, 2013, the Court of Appeals reversed the decision of the District Court. On September 3, 2013, GenOn filed a petition for rehearing with the Court of Appeals which was subsequently denied. In February 2014, NRG filed a petition for a writ of certiorari to the U.S. Supreme Court seeking review and reversal of the Court of Appeals decision. On June 2, 2014, the U.S. Supreme Court denied the petition for a writ of certiorari. The case is proceeding in the U.S. District Court for the Western District of Pennsylvania. | |
Cheswick Monarch Mine NOV (GenOn) | |
In 2008, the PADEP issued an NOV related to the Monarch mine located near the Cheswick generating facility. It has not been mined for many years. GenOn discharged approved wastewaters into the Monarch mine including low-volume wastewater from the Cheswick generating facility and leachate collected from ash disposal facilities. The NOV addresses a permit requirement to pump a minimum water volume from the mine. On September 2, 2014, GenOn's subsidiary that owns the Cheswick generating facility, the Commonwealth of Pennsylvania and the PADEP entered into a Consent Order and Agreement resolving the NOV. Pursuant to that Consent Order and Agreement, GenOn will, among other things, cease wastewater discharges to the mine, construct a waste treatment facility and contribute $200,000 to the Indianola Mine Trust. GenOn is currently planning to incur capital expenditures in connection with wastewater from Cheswick and leachate from ash disposal facilities. | |
Maryland Department of the Environment v. GenOn Chalk Point and GenOn Mid-Atlantic | |
On January 25, 2013, Food & Water Watch, the Patuxent Riverkeeper and the Potomac Riverkeeper (together, the Citizens Group) sent GenOn Mid-Atlantic a letter alleging that the Chalk Point, Dickerson and Morgantown generating facilities were violating the terms of the three National Pollution Discharge Elimination System permits by discharging nitrogen and phosphorous in excess of the limits in each permit. On March 21, 2013, the MDE sent GenOn Mid-Atlantic a similar letter with respect to the Chalk Point and Dickerson facilities, threatening to sue within 60 days if the facilities were not brought into compliance. On June 11, 2013, the Maryland Attorney General on behalf of the MDE filed a complaint in the U.S. District Court for the District of Maryland alleging violations of the CWA and Maryland environmental laws related to water. The lawsuit is ongoing and seeks injunctive relief and civil penalties in excess of $100,000. The Registrants do not expect the resolution of this matter to have a material impact on the Registrants' consolidated financial position, results of operations, or cash flows. | |
Chapter 11 Proceedings (GenOn and GenOn Americas Generation) | |
In July 2003, and various dates thereafter, the Mirant Debtors filed voluntary petitions in the Bankruptcy Court for relief under Chapter 11 of the U.S. Bankruptcy Code. GenOn Energy Holdings and most of the other Mirant Debtors emerged from bankruptcy on January 3, 2006, when the Plan became effective. The remaining Mirant Debtors emerged from bankruptcy on various dates in 2007. Approximately 461,000 of the shares of GenOn Energy Holdings common stock to be distributed under the Plan have not yet been distributed and have been reserved for distribution with respect to claims disputed by the Mirant Debtors that have not been resolved. Upon the Mirant/RRI Merger, those reserved shares converted into a reserve for approximately 1.3 million shares of GenOn common stock. Upon the NRG Merger, those reserved shares converted into a reserve for approximately 159,000 shares of NRG common stock. Under the terms of the Plan, upon the resolution of such a disputed claim, the claimant will receive the same pro rata distributions of common stock, cash, or both as previously allowed claims, regardless of the price at which the common stock is trading at the time the claim is resolved. If the aggregate amount of any such payouts results in the number of reserved shares being insufficient, additional shares of common stock may be issued to address the shortfall. |
Regulatory_Matters
Regulatory Matters | 9 Months Ended |
Sep. 30, 2014 | |
Regulatory Matters Disclosure [Abstract] | ' |
Regulatory Matters (GenOn, GenOn Americas Generation, GenOn Mid-Atlantic) | ' |
Regulatory Matters (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | |
This footnote should be read in conjunction with the complete description under Note 19, Regulatory Matters, to the Registrants' 2013 Form 10-K. | |
The Registrants operate in a highly regulated industry and are subject to regulation by various federal and state agencies. As such, the Registrants are affected by regulatory developments at both the federal and state levels and in the regions in which they operate. In addition, the Registrants are subject to the market rules, procedures, and protocols of the various ISO and RTO markets in which they participate. These power markets are subject to ongoing legislative and regulatory changes that may impact the Registrants' wholesale business. | |
In addition to the regulatory proceedings noted below, the Registrants are parties to other regulatory proceedings arising in the ordinary course of business or have other regulatory exposure. In management's opinion, the disposition of these ordinary course matters will not materially adversely affect the Registrants’ respective consolidated financial position, results of operations, or cash flows. | |
National | |
Court Rejects FERC’s Jurisdiction Over Demand Response — On May 23, 2014, the U.S. Court of Appeals for the District of Columbia Circuit vacated FERC’s rules (known as Order No. 745) that allow demand response resources to participate in the FERC-jurisdictional energy markets. The Court of Appeals held that the Federal Power Act does not authorize FERC to exercise jurisdiction over demand response and that instead demand response is part of the retail market over which the states have jurisdiction. The specific order being challenged related solely to energy market participation, but this ruling also calls into question whether demand response will be permitted to participate in the capacity markets in the future. The U.S. Court of Appeals for the District of Columbia Circuit denied FERC's request to rehear en banc the decision. The decision could be appealed to the U.S. Supreme Court. The eventual outcome of this proceeding could result in refunds of payments made for non-jurisdictional services and resettlement of wholesale markets but it is not possible to estimate the impact on the Registrants at this time. On October 20, 2014, the U.S. Court of Appeals for the District of Columbia Circuit issued a stay of its decision until at least December 16, 2014, with the possibility of a longer stay if the government seeks U.S. Supreme Court review. |
Environmental_Matters
Environmental Matters | 9 Months Ended |
Sep. 30, 2014 | |
Environmental Matters Disclosure [Abstract] | ' |
Environmental Matters (GenOn, GenOn Americas Generation, GenOn Mid-Atlantic) | ' |
Environmental Matters (GenOn, GenOn Americas Generation and GenOn Mid-Atlantic) | |
This footnote should be read in conjunction with the complete description under Note 20, Environmental Matters, to the Registrants' 2013 Form 10-K. | |
The Registrants are subject to a wide range of environmental laws in the development, ownership, construction and operation of projects. These laws generally require that governmental permits and approvals be obtained before construction and during operation of power plants. Environmental laws have become increasingly stringent and the Registrants expect this trend to continue. The electric generation industry is likely to face new requirements to address various emissions, including greenhouse gases, as well as combustion byproducts, water discharge and use, and threatened and endangered species. In general, future laws are expected to require the addition of emissions controls or other environmental controls or to impose certain restrictions on the operations of the Registrants' facilities, which could have a material effect on the Registrants' operations. | |
The EPA released CSAPR in 2011, which was scheduled to replace CAIR in January 2012. In December 2011, the U.S. Court of Appeals for the District of Columbia Circuit stayed the implementation of CSAPR and then issued an opinion in August 2012 vacating CSAPR and keeping CAIR in place until the EPA could replace it. On April 29, 2014, the U.S. Supreme Court reversed and remanded the D.C. Circuit's decision. In October 2014, the D.C. Circuit lifted the stay of CSAPR. Accordingly, the Registrants expect compliance to begin in January 2015. Further proceedings in the Court of Appeals are scheduled to occur over the next few months. While the Registrants are unable to predict the final outcome of the ongoing litigation, the Registrants believe their investment in pollution controls and cleaner technologies coupled with planned plant retirements should leave the fleet well positioned for compliance. | |
In January 2014, EPA re-proposed the NSPS for CO2 emissions from new fossil-fuel-fired electric generating units that had been previously proposed in April 2012. The re-proposed standards are 1,000 pounds of CO2 per MWh for large gas units and 1,100 pounds of CO2 per MWh for coal units and small gas units. Proposed standards are in effect until a final rule is published or another rule is re-proposed. On June 18, 2014, the EPA proposed a rule that would require states to develop CO2 emission standards that would apply to existing fossil-fueled generating facilities. Specifically, the EPA proposed state-specific rate-based standards for CO2 emissions, as well as guidelines for states to follow in developing plans to achieve the state-specific standards. Comments on this proposal are due in December 2014. The EPA anticipates finalizing this rule in June 2015. | |
Water | |
In August 2014, the EPA finalized the regulation regarding once through cooling from existing facilities to address impingement and entrainment concerns. The Registrants anticipate that more stringent requirements will be incorporated into some of their water discharge permits over the next several years. | |
East Region | |
In October 2014, the MDE released a draft of a proposed regulation regarding NOx emissions from coal-fired electric generating units. MDE has stated that the draft will be proposed in the Maryland Register in December 2014 and finalized in 2015. If finalized in its current form, the regulation would require the Registrants to: (1) install and operate state-of-the-art controls (e.g., SCRs) by June 1, 2020 at the three Dickerson coal-fired units and one of the Chalk Point coal-fired units; (2) retire the units; or (3) convert the fuel source for the units from coal to natural gas. The implementation of the MDE regulations could negatively affect certain of the Registrants' coal facilities in Maryland. | |
Environmental Capital Expenditures | |
Based on current rules, technology and preliminary plans based on some proposed rules, GenOn estimates that environmental capital expenditures from 2014 through 2018 required to comply with regulatory environmental laws will be approximately $109 million for GenOn, which includes $15 million for GenOn Americas Generation, which was adjusted for the sale of Kendall on January 31, 2014. The amount for GenOn Americas Generation includes $10 million for GenOn Mid-Atlantic. |
Basis_of_Presentation_Reclassi
Basis of Presentation Reclassification (Policies) | 9 Months Ended |
Sep. 30, 2014 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' |
Reclassification, Policy [Policy Text Block] | ' |
Reclassifications | |
Certain prior year amounts have been reclassified for comparative purposes. The reclassification did not affect results from operations. |
Basis_of_Presentation_Use_of_E
Basis of Presentation Use of Estimates (Policies) | 9 Months Ended |
Sep. 30, 2014 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' |
Use of Estimates, Policy [Policy Text Block] | ' |
Use of Estimates | |
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Certain prior year depreciation amounts have been recast to revise provisional purchase accounting estimates for the NRG Merger. |
Fair_Value_of_Financial_Instru1
Fair Value of Financial Instruments (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2014 | ||||||||||||||||
Fair Value of Financial Instruments | ' | |||||||||||||||
Estimated carrying amounts and fair values of recorded financial instruments not carried at fair market value | ' | |||||||||||||||
The estimated carrying amounts and fair values of GenOn and GenOn Americas Generation’s debt are as follows: | ||||||||||||||||
GenOn | ||||||||||||||||
As of September 30, 2014 | As of December 31, 2013 | |||||||||||||||
Carrying Amount | Fair Value | Carrying Amount | Fair Value | |||||||||||||
(In millions) | ||||||||||||||||
Long and short-term debt | $ | 3,117 | $ | 2,828 | $ | 3,120 | $ | 3,058 | ||||||||
Assets and liabilities measured and recorded at fair value on the consolidated balance sheets on a recurring basis | ' | |||||||||||||||
GenOn | ||||||||||||||||
The following tables present assets and liabilities (including affiliate amounts) measured and recorded at fair value on GenOn’s consolidated balance sheet on a recurring basis and their level within the fair value hierarchy: | ||||||||||||||||
As of September 30, 2014 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 116 | $ | 482 | $ | 16 | $ | 614 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 23 | $ | 408 | $ | 36 | $ | 467 | ||||||||
Other assets (b) | $ | 21 | $ | — | $ | — | $ | 21 | ||||||||
(a) There were no transfers during the three and nine months ended September 30, 2014 between Levels 1 and 2. | ||||||||||||||||
(b) Relates to mutual funds held in a rabbi trust for non-qualified deferred compensation plans for certain key and highly compensated employees. | ||||||||||||||||
As of December 31, 2013 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 141 | $ | 507 | $ | 3 | $ | 651 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 25 | $ | 149 | $ | 7 | $ | 181 | ||||||||
Other assets (b) | $ | 37 | $ | — | $ | — | $ | 37 | ||||||||
(a) There were no transfers during the year ended December 31, 2013 between Levels 1 and 2. | ||||||||||||||||
(b) Relates to mutual funds held in a rabbi trust for non-qualified deferred compensation plans for certain key and highly compensated employees. | ||||||||||||||||
Reconciliation of beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements at least annually using significant unobservable inputs | ' | |||||||||||||||
The following tables reconcile, for the three and nine months ended September 30, 2014 and 2013, the beginning and ending balances for derivatives that are recognized at fair value in GenOn's consolidated financial statements at least annually using significant unobservable inputs: | ||||||||||||||||
Fair Value Measurement Using Significant Unobservable Inputs (Level 3) | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
Derivatives (a) | Derivatives (a) | |||||||||||||||
(In millions) | ||||||||||||||||
Beginning balance | $ | (44 | ) | $ | 3 | $ | (4 | ) | $ | 17 | ||||||
Total gains/(losses) included in earnings — realized/unrealized | 1 | 1 | 3 | (15 | ) | |||||||||||
Purchases | 22 | 1 | (19 | ) | 3 | |||||||||||
Transfers into Level 3 (b) | 1 | — | — | — | ||||||||||||
Ending balance | $ | (20 | ) | $ | 5 | $ | (20 | ) | $ | 5 | ||||||
(Losses)/gains for the period included in earnings attributable to the change in unrealized gains or losses relating to assets or liabilities still held as of September 30 | $ | — | $ | — | $ | (1 | ) | $ | 1 | |||||||
(a) Consists of derivative assets and liabilities, net. | ||||||||||||||||
(b) Transfers in/out of level 3 are related to the availability of external broker quotes and are valued as of the end of the reporting period. | ||||||||||||||||
Schedule of credit reserves for derivative contract assets | ' | |||||||||||||||
The Registrants' credit reserves were as follows: | ||||||||||||||||
As of September 30, 2014 | As of December 31, 2013 | |||||||||||||||
(In millions) | ||||||||||||||||
GenOn | $ | 1 | $ | 1 | ||||||||||||
GenOn Americas Generation | 1 | 1 | ||||||||||||||
GenOn Mid-Atlantic | 1 | 3 | ||||||||||||||
Net counterparty credit exposure by industry sector and by counterparty credit quality | ' | |||||||||||||||
GenOn | ||||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Financial institutions | 68 | % | ||||||||||||||
Utilities, energy merchants, marketers and other | 22 | |||||||||||||||
ISOs | 10 | |||||||||||||||
Total as of September 30, 2014 | 100 | % | ||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Investment grade | 97 | % | ||||||||||||||
Non-rated | 3 | |||||||||||||||
Total as of September 30, 2014 | 100 | % | ||||||||||||||
(a) Counterparty credit exposure excludes transportation contracts because of the unavailability of market prices. | ||||||||||||||||
GenOn Americas Generation | ' | |||||||||||||||
Fair Value of Financial Instruments | ' | |||||||||||||||
Estimated carrying amounts and fair values of recorded financial instruments not carried at fair market value | ' | |||||||||||||||
GenOn Americas Generation | ||||||||||||||||
As of September 30, 2014 | As of December 31, 2013 | |||||||||||||||
Carrying Amount | Fair Value | Carrying Amount | Fair Value | |||||||||||||
(In millions) | ||||||||||||||||
Long and short-term debt | $ | 931 | $ | 786 | $ | 938 | $ | 883 | ||||||||
Assets and liabilities measured and recorded at fair value on the consolidated balance sheets on a recurring basis | ' | |||||||||||||||
GenOn Americas Generation | ||||||||||||||||
The following tables present assets and liabilities (including affiliate amounts) measured and recorded at fair value on GenOn Americas Generation's consolidated balance sheet on a recurring basis and their level within the fair value hierarchy: | ||||||||||||||||
As of September 30, 2014 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 123 | $ | 786 | $ | 31 | $ | 940 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 47 | $ | 675 | $ | 49 | $ | 771 | ||||||||
(a) There were no transfers during the three and nine months ended September 30, 2014 between Levels 1 and 2. | ||||||||||||||||
As of December 31, 2013 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 153 | $ | 575 | $ | 7 | $ | 735 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 74 | $ | 226 | $ | 8 | $ | 308 | ||||||||
(a) There were no transfers during the year ended December 31, 2013 between Levels 1 and 2. | ||||||||||||||||
Reconciliation of beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements at least annually using significant unobservable inputs | ' | |||||||||||||||
The following tables reconcile, for the three and nine months ended September 30, 2014 and 2013, the beginning and ending balances for GenOn Americas Generation's derivatives that are recognized at fair value in the consolidated financial statements at least annually using significant unobservable inputs: | ||||||||||||||||
Fair Value Measurement Using Significant Unobservable Inputs (Level 3) | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
Derivatives (a) | Derivatives (a) | |||||||||||||||
(In millions) | ||||||||||||||||
Beginning balance | $ | (41 | ) | $ | 3 | $ | (1 | ) | $ | 17 | ||||||
Total gains/(losses) included in earnings — realized/unrealized | 1 | — | 1 | (16 | ) | |||||||||||
Purchases | 22 | 1 | (18 | ) | 3 | |||||||||||
Ending balance | $ | (18 | ) | $ | 4 | $ | (18 | ) | $ | 4 | ||||||
Gains/(losses) for the period included in earnings attributable to the change in unrealized gains or losses relating to assets or liabilities still held as of September 30 | $ | 1 | $ | (1 | ) | $ | — | $ | — | |||||||
(a) Consists of derivative assets and liabilities, net. | ||||||||||||||||
Net counterparty credit exposure by industry sector and by counterparty credit quality | ' | |||||||||||||||
GenOn Americas Generation | ||||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Financial institutions | 70 | % | ||||||||||||||
Utilities, energy merchants, marketers and other | 20 | |||||||||||||||
ISOs | 10 | |||||||||||||||
Total as of September 30, 2014 | 100 | % | ||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Investment grade | 99 | % | ||||||||||||||
Non-rated | 1 | |||||||||||||||
Total as of September 30, 2014 | 100 | % | ||||||||||||||
(a) Counterparty credit exposure excludes transportation contracts because of the unavailability of market prices. | ||||||||||||||||
GenOn Mid-Atlantic | ' | |||||||||||||||
Fair Value of Financial Instruments | ' | |||||||||||||||
Assets and liabilities measured and recorded at fair value on the consolidated balance sheets on a recurring basis | ' | |||||||||||||||
GenOn Mid-Atlantic | ||||||||||||||||
The following tables present assets and liabilities (including affiliate amounts) measured and recorded at fair value on GenOn Mid-Atlantic's consolidated balance sheet on a recurring basis and their level within the fair value hierarchy: | ||||||||||||||||
As of September 30, 2014 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 92 | $ | 209 | $ | 1 | $ | 302 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 17 | $ | 91 | $ | 19 | $ | 127 | ||||||||
(a) There were no transfers during the three and nine months ended September 30, 2014 between Levels 1 and 2. | ||||||||||||||||
As of December 31, 2013 | ||||||||||||||||
Fair Value | ||||||||||||||||
Level 1 (a) | Level 2 (a) | Level 3 | Total | |||||||||||||
(In millions) | ||||||||||||||||
Derivative assets: | ||||||||||||||||
Commodity contracts | $ | 87 | $ | 420 | $ | — | $ | 507 | ||||||||
Derivative liabilities: | ||||||||||||||||
Commodity contracts | $ | 13 | $ | 60 | $ | — | $ | 73 | ||||||||
(a) There were no transfers during the year ended December 31, 2013 between Levels 1 and 2. | ||||||||||||||||
Reconciliation of beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements at least annually using significant unobservable inputs | ' | |||||||||||||||
The following tables reconcile, for the three and nine months ended September 30, 2014 and 2013, the beginning and ending balances for GenOn Mid-Atlantic's derivatives that are recognized at fair value in the consolidated financial statements at least annually using significant unobservable inputs: | ||||||||||||||||
Fair Value Measurement Using Significant Unobservable Inputs (Level 3) | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
Derivatives (a) | Derivatives (a) | |||||||||||||||
(In millions) | ||||||||||||||||
Beginning balance | $ | (41 | ) | $ | 2 | $ | — | $ | 7 | |||||||
Total gains/(losses) included in earnings — realized/unrealized | 1 | — | — | (7 | ) | |||||||||||
Purchases | 22 | 1 | (18 | ) | 3 | |||||||||||
Ending balance | $ | (18 | ) | $ | 3 | $ | (18 | ) | $ | 3 | ||||||
Gains for the period included in earnings attributable to the change in unrealized gains or losses relating to assets or liabilities still held as of September 30 | $ | 1 | $ | — | $ | — | $ | 1 | ||||||||
(a) Consists of derivative assets and liabilities, net. | ||||||||||||||||
Net counterparty credit exposure by industry sector and by counterparty credit quality | ' | |||||||||||||||
GenOn Mid-Atlantic | ||||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Financial institutions | 100 | % | ||||||||||||||
Category | Net Exposure (a) | |||||||||||||||
(% of Total) | ||||||||||||||||
Investment grade | 100 | % | ||||||||||||||
(a) Counterparty credit exposure excludes transportation contracts because of the unavailability of market prices. |
Accounting_for_Derivative_Inst1
Accounting for Derivative Instruments and Hedging Activities (Tables) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2014 | |||||||||||||||||
Accounting for Derivative Instruments and Hedging Activities | ' | ||||||||||||||||
Net notional volume buy/(sell) of open derivative transactions broken out by commodity | ' | ||||||||||||||||
The following table summarizes the net notional volume buy/(sell) of the Registrants’ open derivative transactions broken out by commodity, excluding those derivatives that qualified for the NPNS exception as of September 30, 2014 and December 31, 2013. Option contracts are reflected using delta volume. Delta volume equals the notional volume of an option adjusted for the probability that the option will be in-the-money at its expiration date. | |||||||||||||||||
GenOn | GenOn Americas Generation | GenOn Mid-Atlantic | |||||||||||||||
Total Volume | Total Volume | Total Volume | |||||||||||||||
As of September 30, 2014 | As of December 31, 2013 | As of September 30, 2014 | As of December 31, 2013 | As of September 30, 2014 | As of December 31, 2013 | ||||||||||||
Commodity | Units | (In millions) | |||||||||||||||
Coal | Short Ton | 10 | 6 | 7 | 4 | 7 | 4 | ||||||||||
Natural Gas | MMBtu | (47 | ) | -111 | (55 | ) | -113 | (59 | ) | -119 | |||||||
Power | MWh | (38 | ) | -26 | (19 | ) | -14 | (18 | ) | -14 | |||||||
Fair value within the derivative instrument valuation on the balance sheets | ' | ||||||||||||||||
The following tables summarize the fair value within the derivative instrument valuation on the balance sheet: | |||||||||||||||||
GenOn | |||||||||||||||||
Fair Value | |||||||||||||||||
Derivative Assets | Derivative Liabilities | ||||||||||||||||
30-Sep-14 | 31-Dec-13 | 30-Sep-14 | 31-Dec-13 | ||||||||||||||
(In millions) | |||||||||||||||||
Derivatives Not Designated as Cash Flow Hedges: | |||||||||||||||||
Commodity contracts current | $ | 451 | $ | 469 | $ | 419 | $ | 163 | |||||||||
Commodity contracts long-term | 163 | 182 | 48 | 18 | |||||||||||||
Total Derivatives Not Designated as Cash Flow Hedges | $ | 614 | $ | 651 | $ | 467 | $ | 181 | |||||||||
Offsetting of derivatives by counterparty master agreement level and collateral received or paid | ' | ||||||||||||||||
The following tables summarize the offsetting of derivatives by counterparty master agreement level and collateral received or paid: | |||||||||||||||||
GenOn | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
September 30, 2014 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 608 | $ | (435 | ) | $ | — | $ | 173 | ||||||||
Derivative assets - affiliate | 6 | (6 | ) | — | — | ||||||||||||
Derivative liabilities | (453 | ) | 435 | 3 | (15 | ) | |||||||||||
Derivative liabilities - affiliate | (14 | ) | 6 | — | (8 | ) | |||||||||||
Total derivative instruments | $ | 147 | $ | — | $ | 3 | $ | 150 | |||||||||
GenOn | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
December 31, 2013 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 645 | $ | (154 | ) | $ | (56 | ) | $ | 435 | |||||||
Derivative assets - affiliate | 6 | (3 | ) | — | 3 | ||||||||||||
Derivative liabilities | (178 | ) | 154 | — | (24 | ) | |||||||||||
Derivative liabilities - affiliate | (3 | ) | 3 | — | — | ||||||||||||
Total derivative instruments | $ | 470 | $ | — | $ | (56 | ) | $ | 414 | ||||||||
Effects of ASC 815 on accumulated OCI balance attributable to cash flow hedge derivatives, net of tax | ' | ||||||||||||||||
The following table summarizes the effects on GenOn's accumulated OCI balance attributable to cash flow hedge derivatives: | |||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Accumulated OCI balance, beginning of period | $ | — | $ | 18 | $ | — | $ | 1 | |||||||||
Recognized in OCI on interest rate derivatives | — | — | — | 19 | |||||||||||||
Reclassified from accumulated OCI into earnings(a)(b) | — | — | — | (2 | ) | ||||||||||||
Reversal as part of sale to NRG Yield LLC(c) | — | (18 | ) | — | (18 | ) | |||||||||||
Accumulated OCI balance, end of period | $ | — | $ | — | $ | — | $ | — | |||||||||
(a) | Amounts reclassified from accumulated OCI into income and amounts recognized in income from the ineffective portion of cash flow hedges are recorded in interest expense. | ||||||||||||||||
(b) | All of the forecasted transactions (future interest payments) were deemed probable of occurring; therefore, no cash flow hedges were discontinued and no amount was recognized in GenOn’s results of operations as a result of discontinued cash flow hedges. | ||||||||||||||||
(c) | The reversal of accumulated OCI as part of the sale of NRG Marsh Landing to NRG Yield LLC resulted in the recognition of additional paid in capital. | ||||||||||||||||
Pre-tax effects of economic hedges that have not been designated as cash flow hedges and trading activity on the statements of operations | ' | ||||||||||||||||
The following tables summarize the pre-tax effects of economic hedges that have not been designated as cash flow hedges and trading activity on the Registrants’ statements of operations. These amounts are included within operating revenues and cost of operations. | |||||||||||||||||
GenOn | |||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Unrealized mark-to-market results | |||||||||||||||||
Reversal of previously recognized unrealized gains on settled positions related to economic hedges | $ | (59 | ) | $ | (73 | ) | $ | (210 | ) | $ | (270 | ) | |||||
Net unrealized gains/(losses) on open positions related to economic hedges | 57 | 18 | (112 | ) | 56 | ||||||||||||
Total unrealized mark-to-market losses for economic hedging activities | (2 | ) | (55 | ) | (322 | ) | (214 | ) | |||||||||
Reversal of previously recognized unrealized gains on settled positions related to trading activity | — | (1 | ) | (1 | ) | (3 | ) | ||||||||||
Net unrealized (losses)/gains on open positions related to trading activity | — | (1 | ) | — | 1 | ||||||||||||
Total unrealized mark-to-market losses for trading activity | — | (2 | ) | (1 | ) | (2 | ) | ||||||||||
Total unrealized losses | $ | (2 | ) | $ | (57 | ) | $ | (323 | ) | $ | (216 | ) | |||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Revenue from operations — energy commodities | $ | 3 | $ | (48 | ) | $ | (341 | ) | $ | (238 | ) | ||||||
Cost of operations | (5 | ) | (9 | ) | 18 | 22 | |||||||||||
Total impact to statements of operations | $ | (2 | ) | $ | (57 | ) | $ | (323 | ) | $ | (216 | ) | |||||
GenOn Americas Generation | ' | ||||||||||||||||
Accounting for Derivative Instruments and Hedging Activities | ' | ||||||||||||||||
Fair value within the derivative instrument valuation on the balance sheets | ' | ||||||||||||||||
GenOn Americas Generation | |||||||||||||||||
Fair Value | |||||||||||||||||
Derivative Assets | Derivative Liabilities | ||||||||||||||||
30-Sep-14 | 31-Dec-13 | 30-Sep-14 | 31-Dec-13 | ||||||||||||||
(In millions) | |||||||||||||||||
Derivatives Not Designated as Cash Flow Hedges: | |||||||||||||||||
Commodity contracts current | $ | 747 | $ | 546 | $ | 678 | $ | 267 | |||||||||
Commodity contracts long-term | 193 | 189 | 93 | 41 | |||||||||||||
Total Derivatives Not Designated as Cash Flow Hedges | $ | 940 | $ | 735 | $ | 771 | $ | 308 | |||||||||
Offsetting of derivatives by counterparty master agreement level and collateral received or paid | ' | ||||||||||||||||
GenOn Americas Generation | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
September 30, 2014 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 608 | $ | (435 | ) | $ | — | $ | 173 | ||||||||
Derivative assets - affiliate | 332 | (318 | ) | — | 14 | ||||||||||||
Derivative liabilities | (453 | ) | 435 | 3 | (15 | ) | |||||||||||
Derivative liabilities - affiliate | (318 | ) | 318 | — | — | ||||||||||||
Total derivative instruments | $ | 169 | $ | — | $ | 3 | $ | 172 | |||||||||
GenOn Americas Generation | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
December 31, 2013 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 643 | $ | (154 | ) | $ | (56 | ) | $ | 433 | |||||||
Derivative assets - affiliate | 92 | (92 | ) | — | — | ||||||||||||
Derivative liabilities | (178 | ) | 154 | — | (24 | ) | |||||||||||
Derivative liabilities - affiliate | (130 | ) | 92 | — | (38 | ) | |||||||||||
Total derivative instruments | $ | 427 | $ | — | $ | (56 | ) | $ | 371 | ||||||||
Pre-tax effects of economic hedges that have not been designated as cash flow hedges and trading activity on the statements of operations | ' | ||||||||||||||||
GenOn Americas Generation | |||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Unrealized mark-to-market results | |||||||||||||||||
Reversal of previously recognized unrealized gains on settled positions related to economic hedges | $ | (65 | ) | $ | (69 | ) | $ | (201 | ) | $ | (218 | ) | |||||
Net unrealized gains/(losses) on open positions related to economic hedges | 30 | 11 | (55 | ) | 37 | ||||||||||||
Total unrealized mark-to-market losses for economic hedging activities | (35 | ) | (58 | ) | (256 | ) | (181 | ) | |||||||||
Reversal of previously recognized unrealized gains on settled positions related to trading activity | — | (1 | ) | (1 | ) | (3 | ) | ||||||||||
Net unrealized (losses)/gains on open positions related to trading activity | — | (1 | ) | — | 1 | ||||||||||||
Total unrealized mark-to-market losses for trading activity | — | (2 | ) | (1 | ) | (2 | ) | ||||||||||
Total unrealized losses | $ | (35 | ) | $ | (60 | ) | $ | (257 | ) | $ | (183 | ) | |||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Revenue from operations — energy commodities | $ | (27 | ) | $ | (52 | ) | $ | (266 | ) | $ | (205 | ) | |||||
Cost of operations | (8 | ) | (8 | ) | 9 | 22 | |||||||||||
Total impact to statements of operations | $ | (35 | ) | $ | (60 | ) | $ | (257 | ) | $ | (183 | ) | |||||
GenOn Mid-Atlantic | ' | ||||||||||||||||
Accounting for Derivative Instruments and Hedging Activities | ' | ||||||||||||||||
Fair value within the derivative instrument valuation on the balance sheets | ' | ||||||||||||||||
GenOn Mid-Atlantic | |||||||||||||||||
Fair Value | |||||||||||||||||
Derivative Assets | Derivative Liabilities | ||||||||||||||||
30-Sep-14 | 31-Dec-13 | 30-Sep-14 | 31-Dec-13 | ||||||||||||||
(In millions) | |||||||||||||||||
Derivatives Not Designated as Cash Flow Hedges: | |||||||||||||||||
Commodity contracts current | $ | 185 | $ | 351 | $ | 109 | $ | 64 | |||||||||
Commodity contracts long-term | 117 | 156 | 18 | 9 | |||||||||||||
Total Derivatives Not Designated as Cash Flow Hedges | $ | 302 | $ | 507 | $ | 127 | $ | 73 | |||||||||
Offsetting of derivatives by counterparty master agreement level and collateral received or paid | ' | ||||||||||||||||
GenOn Mid-Atlantic | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
September 30, 2014 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 142 | $ | (5 | ) | $ | — | $ | 137 | ||||||||
Derivative assets - affiliate | 160 | (122 | ) | — | 38 | ||||||||||||
Derivative liabilities | (5 | ) | 5 | — | — | ||||||||||||
Derivative liabilities - affiliate | (122 | ) | 122 | — | — | ||||||||||||
Total derivative instruments | $ | 175 | $ | — | $ | — | $ | 175 | |||||||||
GenOn Mid-Atlantic | |||||||||||||||||
Gross Amounts Not Offset in the Statement of Financial Position | |||||||||||||||||
Description | Gross Amounts of Recognized Assets / Liabilities | Derivative Instruments | Cash Collateral (Held) / Posted | Net Amount | |||||||||||||
December 31, 2013 | (In millions) | ||||||||||||||||
Commodity contracts: | |||||||||||||||||
Derivative assets | $ | 358 | $ | — | $ | — | $ | 358 | |||||||||
Derivative assets - affiliate | 149 | (73 | ) | — | 76 | ||||||||||||
Derivative liabilities | — | — | — | — | |||||||||||||
Derivative liabilities - affiliate | (73 | ) | 73 | — | — | ||||||||||||
Total derivative instruments | $ | 434 | $ | — | $ | — | $ | 434 | |||||||||
Pre-tax effects of economic hedges that have not been designated as cash flow hedges and trading activity on the statements of operations | ' | ||||||||||||||||
GenOn Mid-Atlantic | |||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Unrealized mark-to-market results | |||||||||||||||||
Reversal of previously recognized unrealized gains on settled positions related to economic hedges | $ | (63 | ) | $ | (70 | ) | $ | (203 | ) | $ | (220 | ) | |||||
Net unrealized gains/(losses) on open positions related to economic hedges | 31 | 11 | (54 | ) | 39 | ||||||||||||
Total unrealized losses | $ | (32 | ) | $ | (59 | ) | $ | (257 | ) | $ | (181 | ) | |||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||
(In millions) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
Revenue from operations — energy commodities | $ | (24 | ) | $ | (51 | ) | $ | (267 | ) | $ | (203 | ) | |||||
Cost of operations | (8 | ) | (8 | ) | 10 | 22 | |||||||||||
Total impact to statements of operations | $ | (32 | ) | $ | (59 | ) | $ | (257 | ) | $ | (181 | ) |
Income_Taxes_Tables
Income Taxes (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2014 | ||||||||||||||||
Income Tax Disclosure [Abstract] | ' | |||||||||||||||
Income tax (benefit)/provision | ' | |||||||||||||||
GenOn’s income tax expense/(benefit) consisted of the following: | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
(In millions except otherwise noted) | 2014 | 2013 | 2014 | 2013 | ||||||||||||
Income/(loss) before income taxes | $ | 46 | $ | 101 | $ | 26 | $ | (69 | ) | |||||||
Income tax expense/(benefit) | — | — | 2 | (6 | ) | |||||||||||
Effective tax rate | — | % | — | % | 7.7 | % | 8.7 | % |
Related_Party_Transactions_Tab
Related Party Transactions (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2014 | ||||||||||||||||
GenOn Americas Generation | ' | |||||||||||||||
Related Party Transaction | ' | |||||||||||||||
Summary of material related-party transactions with affiliates | ' | |||||||||||||||
The following costs were incurred under these arrangements: | ||||||||||||||||
GenOn Americas Generation | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
(In millions) | ||||||||||||||||
Allocated costs: | ||||||||||||||||
Cost of operations — affiliate | $ | — | $ | 2 | $ | 1 | $ | 7 | ||||||||
Selling, general and administrative — affiliate | 20 | 18 | 62 | 57 | ||||||||||||
Total | $ | 20 | $ | 20 | $ | 63 | $ | 64 | ||||||||
GenOn Mid-Atlantic | ' | |||||||||||||||
Related Party Transaction | ' | |||||||||||||||
Summary of material related-party transactions with affiliates | ' | |||||||||||||||
GenOn Mid-Atlantic | ||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
(In millions) | ||||||||||||||||
Allocated costs: | ||||||||||||||||
Cost of operations — affiliate | $ | — | $ | 2 | $ | — | $ | 5 | ||||||||
Selling, general and administrative — affiliate | 17 | 15 | 52 | 48 | ||||||||||||
Total | $ | 17 | $ | 17 | $ | 52 | $ | 53 | ||||||||
Basis_of_Presentation_Details
Basis of Presentation (Details) | Sep. 30, 2014 |
MW | |
Basis of Presentation | ' |
Generation capacity (in MW) | 19,583 |
GenOn Mid-Atlantic | ' |
Basis of Presentation | ' |
Generation capacity (in MW) | 4,683 |
GenOn Americas Generation | ' |
Basis of Presentation | ' |
Generation capacity (in MW) | 7,596 |
Summary_of_Significant_Account1
Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Accounting Policies [Abstract] | ' | ' | ' | ' |
Impairment of Long-Lived Assets to be Disposed of | $60 | $0 | $60 | $0 |
Fair_Value_of_Financial_Instru2
Fair Value of Financial Instruments (Details) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
In Millions, unless otherwise specified | ||
Carrying Amount | ' | ' |
Fair Value of Financial Instruments | ' | ' |
Long-term debt | $3,117 | $3,120 |
Fair Value | ' | ' |
Fair Value of Financial Instruments | ' | ' |
Long-term debt | 2,828 | 3,058 |
GenOn Americas Generation | Carrying Amount | ' | ' |
Fair Value of Financial Instruments | ' | ' |
Long-term debt | 931 | 938 |
GenOn Americas Generation | Fair Value | ' | ' |
Fair Value of Financial Instruments | ' | ' |
Long-term debt | $786 | $883 |
Fair_Value_of_Financial_Instru3
Fair Value of Financial Instruments (Details 2) (Fair Value, Measurements, Recurring, USD $) | Sep. 30, 2014 | Dec. 31, 2013 | ||
In Millions, unless otherwise specified | ||||
Level 1 | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Other assets | $21 | [1],[2] | $37 | [2],[3] |
Level 1 | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 116 | [1] | 141 | [3] |
Derivative liabilities | 23 | [1] | 25 | [3] |
Level 2 | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Other assets | 0 | [1],[2] | 0 | [2],[3] |
Level 2 | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 482 | [1] | 507 | [3] |
Derivative liabilities | 408 | [1] | 149 | [3] |
Fair Value, Inputs, Level 3 [Member] | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Other assets | 0 | [2] | 0 | [2] |
Fair Value, Inputs, Level 3 [Member] | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 16 | 3 | ||
Derivative liabilities | 36 | 7 | ||
Fair Value | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Other assets | 21 | [2] | 37 | [2] |
Fair Value | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 614 | 651 | ||
Derivative liabilities | 467 | 181 | ||
GenOn Americas Generation | Level 1 | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 123 | [1] | 153 | [3] |
Derivative liabilities | 47 | [1] | 74 | [3] |
GenOn Americas Generation | Level 2 | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 786 | [1] | 575 | [3] |
Derivative liabilities | 675 | [1] | 226 | [3] |
GenOn Americas Generation | Fair Value, Inputs, Level 3 [Member] | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 31 | 7 | ||
Derivative liabilities | 49 | 8 | ||
GenOn Americas Generation | Fair Value | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 940 | 735 | ||
Derivative liabilities | 771 | 308 | ||
GenOn Mid-Atlantic | Level 1 | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 92 | [1] | 87 | [3] |
Derivative liabilities | 17 | [1] | 13 | [3] |
GenOn Mid-Atlantic | Level 2 | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 209 | [1] | 420 | [3] |
Derivative liabilities | 91 | [1] | 60 | [3] |
GenOn Mid-Atlantic | Fair Value, Inputs, Level 3 [Member] | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 1 | 0 | ||
Derivative liabilities | 19 | 0 | ||
GenOn Mid-Atlantic | Fair Value | Commodity contracts | ' | ' | ||
Fair Value Assets and Liabilities, Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ||
Derivative Asset, Fair Value, Gross Asset | 302 | 507 | ||
Derivative liabilities | $127 | $73 | ||
[1] | There were no transfers during the three and nine months ended September 30, 2014 between Levels 1 and 2. | |||
[2] | Relates to mutual funds held in a rabbi trust for non-qualified deferred compensation plans for certain key and highly compensated employees | |||
[3] | There were no transfers during the year ended December 31, 2013 between Levels 1 and 2. |
Fair_Value_of_Financial_Instru4
Fair Value of Financial Instruments (Details 3) (Fair Value, Inputs, Level 3 [Member], Derivative [Member], USD $) | 3 Months Ended | 9 Months Ended | ||||||||||||||
In Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Jun. 30, 2014 | Dec. 31, 2013 | Jun. 30, 2013 | Dec. 31, 2012 | ||||||||
Fair Value Asset and Liabilities, Measured on Recurring Basis, Unobservable Input Changes | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs | ($20) | [1] | $5 | [1] | ($20) | [1] | $5 | [1] | ($44) | [1] | ($4) | [1] | $3 | [1] | $17 | [1] |
Reconciliation of the beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
Total gains and losses (realized/unrealized) included in earnings | 1 | [1] | 1 | [1] | 3 | [1] | -15 | [1] | ' | ' | ' | ' | ||||
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases | 22 | [1] | 1 | [1] | -19 | [1] | 3 | [1] | ' | ' | ' | ' | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset and Liability Transfers into Level 3 | 1 | [1],[2] | 0 | [1],[2] | 0 | [1],[2] | 0 | [1],[2] | ' | ' | ' | ' | ||||
Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings | 0 | [1] | 0 | [1] | -1 | [1] | 1 | [1] | ' | ' | ' | ' | ||||
GenOn Americas Generation | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
Fair Value Asset and Liabilities, Measured on Recurring Basis, Unobservable Input Changes | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs | -18 | [1] | 4 | [1] | -18 | [1] | 4 | [1] | -41 | [1] | -1 | [1] | 3 | [1] | 17 | [1] |
Reconciliation of the beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
Total gains and losses (realized/unrealized) included in earnings | 1 | [1] | 0 | [1] | 1 | [1] | -16 | [1] | ' | ' | ' | ' | ||||
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases | 22 | [1] | 1 | [1] | -18 | [1] | 3 | [1] | ' | ' | ' | ' | ||||
Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings | 1 | [1] | -1 | [1] | 0 | 0 | [1] | ' | ' | ' | ' | |||||
GenOn Mid-Atlantic | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
Fair Value Asset and Liabilities, Measured on Recurring Basis, Unobservable Input Changes | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs | -18 | [3] | 3 | [3] | -18 | [3] | 3 | [3] | -41 | [3] | 0 | [3] | 2 | [3] | 7 | [3] |
Reconciliation of the beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
Total gains and losses (realized/unrealized) included in earnings | 1 | [3] | 0 | [3] | 0 | [3] | -7 | [3] | ' | ' | ' | ' | ||||
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases | 22 | [3] | 1 | [3] | -18 | [3] | 3 | [3] | ' | ' | ' | ' | ||||
Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings | $1 | [3] | $0 | [3] | $0 | [3] | $1 | [3] | ' | ' | ' | ' | ||||
[1] | Consists of derivative assets and liabilities, net. | |||||||||||||||
[2] | Transfers in/out of level 3 are related to the availability of external broker quotes and are valued as of the end of the reporting period. | |||||||||||||||
[3] | Consists of derivative assets and liabilities, net |
Fair_Value_of_Financial_Instru5
Fair Value of Financial Instruments (Details 4) (USD $) | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2014 | Dec. 31, 2013 | |
Derivative fair value measurements | ' | ' | |
Total derivative assets valued with prices provied by models and other valuation techniques (as a percent) | 3.00% | ' | |
Total derivative liabilities valued with prices provied by models and other valuation techniques (as a percent) | 8.00% | ' | |
Credit reserve balance | $1 | $1 | |
Concentration of credit risk | ' | ' | |
Counterparty credit exposure | 269 | ' | |
Collateral held (cash and letters of credit) against counterparty credit exposure | 0 | ' | |
Counterparty credit exposure, net | 269 | ' | |
Counterparty credit exposure before collateral expected to roll off by the end of 2014 (as a percent) | 78.00% | ' | |
Net exposure (as a percent) | 100.00% | [1] | ' |
Fair Value Inputs, Counterparty Credit Risk | 10.00% | ' | |
Aggregate counterparty credit risk exposure for counterparties representing exposure above threshold percentage | 163 | ' | |
Investment grade | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 97.00% | [1] | ' |
Non-rated | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 3.00% | [1] | ' |
Financial institutions | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 68.00% | [1] | ' |
Utilities, energy merchants, marketers and other | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 22.00% | [1] | ' |
ISOs | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 10.00% | [1] | ' |
GenOn Americas Generation | ' | ' | |
Derivative fair value measurements | ' | ' | |
Total derivative assets valued with prices provied by models and other valuation techniques (as a percent) | 3.00% | ' | |
Total derivative liabilities valued with prices provied by models and other valuation techniques (as a percent) | 6.00% | ' | |
Credit reserve balance | 1 | 1 | |
Concentration of credit risk | ' | ' | |
Counterparty credit exposure | 262 | ' | |
Collateral held (cash and letters of credit) against counterparty credit exposure | 0 | ' | |
Counterparty credit exposure, net | 262 | ' | |
Counterparty credit exposure before collateral expected to roll off by the end of 2014 (as a percent) | 79.00% | ' | |
Net exposure (as a percent) | 100.00% | [1] | ' |
Fair Value Inputs, Counterparty Credit Risk | 10.00% | ' | |
Aggregate counterparty credit risk exposure for counterparties representing exposure above threshold percentage | 163 | ' | |
GenOn Americas Generation | Investment grade | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 99.00% | [1] | ' |
GenOn Americas Generation | Non-rated | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 1.00% | [1] | ' |
GenOn Americas Generation | Financial institutions | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 70.00% | [1] | ' |
GenOn Americas Generation | Utilities, energy merchants, marketers and other | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 20.00% | [1] | ' |
GenOn Americas Generation | ISOs | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 10.00% | [1] | ' |
GenOn Mid-Atlantic | ' | ' | |
Derivative fair value measurements | ' | ' | |
Total derivative assets valued with prices provied by models and other valuation techniques (as a percent) | 0.00% | ' | |
Total derivative liabilities valued with prices provied by models and other valuation techniques (as a percent) | 15.00% | ' | |
Credit reserve balance | 1 | 3 | |
Concentration of credit risk | ' | ' | |
Counterparty credit exposure | 142 | ' | |
Collateral held (cash and letters of credit) against counterparty credit exposure | 0 | ' | |
Counterparty credit exposure, net | 142 | ' | |
Counterparty credit exposure before collateral expected to roll off by the end of 2014 (as a percent) | 100.00% | ' | |
Fair Value Inputs, Counterparty Credit Risk | 10.00% | ' | |
Aggregate counterparty credit risk exposure for counterparties representing exposure above threshold percentage | $136 | ' | |
GenOn Mid-Atlantic | Investment grade | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 100.00% | [1] | ' |
GenOn Mid-Atlantic | Financial institutions | ' | ' | |
Concentration of credit risk | ' | ' | |
Net exposure (as a percent) | 100.00% | [1] | ' |
[1] | Counterparty credit exposure excludes transportation contracts because of the unavailability of market prices. |
Accounting_for_Derivative_Inst2
Accounting for Derivative Instruments and Hedging Activities Disclosure Accounting for Derivative Instruments and Hedging Activities (Details 1) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2014 | Dec. 31, 2013 | |
T | T | |
Coal | Short Ton [Member] | ' | ' |
Derivative | ' | ' |
Derivative, Nonmonetary Notional Amount, Mass | 10,000,000 | 6,000,000 |
Coal | Short Ton [Member] | GenOn Americas Generation | ' | ' |
Derivative | ' | ' |
Derivative, Nonmonetary Notional Amount, Mass | 7,000,000 | 4,000,000 |
Coal | Short Ton [Member] | GenOn Mid-Atlantic | ' | ' |
Derivative | ' | ' |
Derivative, Nonmonetary Notional Amount, Mass | 7,000,000 | 4,000,000 |
Natural Gas [Member] | MMbtu [Member] | ' | ' |
Derivative | ' | ' |
Derivative, Nonmonetary Notional Amount, Energy Measure | -47,000,000 | -111,000,000 |
Natural Gas [Member] | MMbtu [Member] | GenOn Americas Generation | ' | ' |
Derivative | ' | ' |
Derivative, Nonmonetary Notional Amount, Energy Measure | -55,000,000 | -113,000,000 |
Natural Gas [Member] | MMbtu [Member] | GenOn Mid-Atlantic | ' | ' |
Derivative | ' | ' |
Derivative, Nonmonetary Notional Amount, Energy Measure | -59,000,000 | -119,000,000 |
Power [Member] | M Wh [Member] | ' | ' |
Derivative | ' | ' |
Derivative, Nonmonetary Notional Amount, Energy Measure | -38,000,000 | -26,000,000 |
Power [Member] | M Wh [Member] | GenOn Americas Generation | ' | ' |
Derivative | ' | ' |
Derivative, Nonmonetary Notional Amount, Energy Measure | -19,000,000 | -14,000,000 |
Power [Member] | M Wh [Member] | GenOn Mid-Atlantic | ' | ' |
Derivative | ' | ' |
Derivative, Nonmonetary Notional Amount, Energy Measure | -18,000,000 | -14,000,000 |
Accounting_for_Derivative_Inst3
Accounting for Derivative Instruments and Hedging Activities Disclosure Accounting for Derivative Instruments and Hedging Activities (Details 2) (Not Designated as Hedging Instrument [Member], USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
In Millions, unless otherwise specified | ||
Derivative | ' | ' |
Derivative Asset, Fair Value, Gross Asset | $614 | $651 |
Derivative Liability, Fair Value, Gross Liability | 467 | 181 |
GenOn Americas Generation | ' | ' |
Derivative | ' | ' |
Derivative Asset, Fair Value, Gross Asset | 940 | 735 |
Derivative Liability, Fair Value, Gross Liability | 771 | 308 |
GenOn Mid-Atlantic | ' | ' |
Derivative | ' | ' |
Derivative Asset, Fair Value, Gross Asset | 302 | 507 |
Derivative Liability, Fair Value, Gross Liability | 127 | 73 |
Commodity Contract Current [Member] | ' | ' |
Derivative | ' | ' |
Derivative Asset, Fair Value, Gross Asset | 451 | 469 |
Derivative Liability, Fair Value, Gross Liability | 419 | 163 |
Commodity Contract Current [Member] | GenOn Americas Generation | ' | ' |
Derivative | ' | ' |
Derivative Asset, Fair Value, Gross Asset | 747 | 546 |
Derivative Liability, Fair Value, Gross Liability | 678 | 267 |
Commodity Contract Current [Member] | GenOn Mid-Atlantic | ' | ' |
Derivative | ' | ' |
Derivative Asset, Fair Value, Gross Asset | 185 | 351 |
Derivative Liability, Fair Value, Gross Liability | 109 | 64 |
Commodity Contract Non Current [Member] | ' | ' |
Derivative | ' | ' |
Derivative Asset, Fair Value, Gross Asset | 163 | 182 |
Derivative Liability, Fair Value, Gross Liability | 48 | 18 |
Commodity Contract Non Current [Member] | GenOn Americas Generation | ' | ' |
Derivative | ' | ' |
Derivative Asset, Fair Value, Gross Asset | 193 | 189 |
Derivative Liability, Fair Value, Gross Liability | 93 | 41 |
Commodity Contract Non Current [Member] | GenOn Mid-Atlantic | ' | ' |
Derivative | ' | ' |
Derivative Asset, Fair Value, Gross Asset | 117 | 156 |
Derivative Liability, Fair Value, Gross Liability | $18 | $9 |
Accounting_for_Derivative_Inst4
Accounting for Derivative Instruments and Hedging Activities (Details 3) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
In Millions, unless otherwise specified | ||
Fair Value of Derivative Instruments/Offsetting of Derivatives by Counterparty Master Agreement Level and Collateral Received or Paid | ' | ' |
Cash Collateral (Held) | $0 | ($56) |
Cash Collateral Posted | -135 | -62 |
Gross Amounts of Recognized Assets / Liabilities | 147 | 470 |
Derivative Instruments | 0 | 0 |
Cash Collateral (Held) / Posted | 3 | -56 |
Net Amount | 150 | 414 |
GenOn Americas Generation | ' | ' |
Fair Value of Derivative Instruments/Offsetting of Derivatives by Counterparty Master Agreement Level and Collateral Received or Paid | ' | ' |
Cash Collateral (Held) | 0 | -56 |
Cash Collateral Posted | -125 | -50 |
Gross Amounts of Recognized Assets / Liabilities | 169 | 427 |
Derivative Instruments | 0 | 0 |
Cash Collateral (Held) / Posted | 3 | -56 |
Net Amount | 172 | 371 |
GenOn Mid-Atlantic | ' | ' |
Fair Value of Derivative Instruments/Offsetting of Derivatives by Counterparty Master Agreement Level and Collateral Received or Paid | ' | ' |
Gross Amounts of Recognized Assets / Liabilities | 175 | 434 |
Derivative Instruments | 0 | 0 |
Cash Collateral (Held) / Posted | 0 | 0 |
Net Amount | 175 | 434 |
Non-affiliate | Commodity contracts | ' | ' |
Fair Value of Derivative Instruments/Offsetting of Derivatives by Counterparty Master Agreement Level and Collateral Received or Paid | ' | ' |
Gross Amount of Recognized Derivative Assets | 608 | 645 |
Gross Amounts of Recognized Derivative Liabilities | -453 | -178 |
Derivative Instruments | -435 | -154 |
Derivative Instruments | 435 | 154 |
Cash Collateral (Held) | 0 | -56 |
Cash Collateral Posted | 3 | 0 |
Net Amount | 173 | 435 |
Net Amount | -15 | -24 |
Non-affiliate | GenOn Americas Generation | Commodity contracts | ' | ' |
Fair Value of Derivative Instruments/Offsetting of Derivatives by Counterparty Master Agreement Level and Collateral Received or Paid | ' | ' |
Gross Amount of Recognized Derivative Assets | 608 | 643 |
Gross Amounts of Recognized Derivative Liabilities | -453 | -178 |
Derivative Instruments | -435 | -154 |
Derivative Instruments | 435 | 154 |
Cash Collateral (Held) | 0 | -56 |
Cash Collateral Posted | 3 | 0 |
Net Amount | 173 | 433 |
Net Amount | -15 | -24 |
Non-affiliate | GenOn Mid-Atlantic | Commodity contracts | ' | ' |
Fair Value of Derivative Instruments/Offsetting of Derivatives by Counterparty Master Agreement Level and Collateral Received or Paid | ' | ' |
Gross Amount of Recognized Derivative Assets | 142 | 358 |
Gross Amounts of Recognized Derivative Liabilities | -5 | 0 |
Derivative Instruments | -5 | 0 |
Derivative Instruments | 5 | 0 |
Cash Collateral (Held) | 0 | 0 |
Cash Collateral Posted | 0 | 0 |
Net Amount | 137 | 358 |
Net Amount | 0 | 0 |
Affiliate | Commodity contracts | ' | ' |
Fair Value of Derivative Instruments/Offsetting of Derivatives by Counterparty Master Agreement Level and Collateral Received or Paid | ' | ' |
Gross Amount of Recognized Derivative Assets | 6 | 6 |
Gross Amounts of Recognized Derivative Liabilities | -14 | -3 |
Derivative Instruments | -6 | -3 |
Derivative Instruments | 6 | 3 |
Cash Collateral (Held) | 0 | 0 |
Cash Collateral Posted | 0 | 0 |
Net Amount | 0 | 3 |
Net Amount | -8 | 0 |
Affiliate | GenOn Americas Generation | Commodity contracts | ' | ' |
Fair Value of Derivative Instruments/Offsetting of Derivatives by Counterparty Master Agreement Level and Collateral Received or Paid | ' | ' |
Gross Amount of Recognized Derivative Assets | 332 | 92 |
Gross Amounts of Recognized Derivative Liabilities | -318 | -130 |
Derivative Instruments | -318 | -92 |
Derivative Instruments | 318 | 92 |
Cash Collateral (Held) | 0 | 0 |
Cash Collateral Posted | 0 | 0 |
Net Amount | 14 | 0 |
Net Amount | 0 | -38 |
Affiliate | GenOn Mid-Atlantic | Commodity contracts | ' | ' |
Fair Value of Derivative Instruments/Offsetting of Derivatives by Counterparty Master Agreement Level and Collateral Received or Paid | ' | ' |
Gross Amount of Recognized Derivative Assets | 160 | 149 |
Gross Amounts of Recognized Derivative Liabilities | -122 | -73 |
Derivative Instruments | -122 | -73 |
Derivative Instruments | 122 | 73 |
Cash Collateral (Held) | 0 | 0 |
Cash Collateral Posted | 0 | 0 |
Net Amount | 38 | 76 |
Net Amount | $0 | $0 |
Accounting_for_Derivative_Inst5
Accounting for Derivative Instruments and Hedging Activities (Details 4) (USD $) | 3 Months Ended | 9 Months Ended | ||||||
In Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | ||||
Effects GenOn's Accumulated OCI Balance Attributable to Cash Flow Hedge Derivatives | ' | ' | ' | ' | ||||
Accumulated OCI balance, beginning of period | $0 | $18 | $0 | $1 | ||||
Recognized in OCI on interest rate derivatives | 0 | 0 | 0 | 19 | ||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax | 0 | [1],[2] | 0 | [1],[2] | 0 | [1],[2] | -2 | [1],[2] |
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax | 0 | [3] | -18 | [3] | 0 | [3] | -18 | [3] |
Accumulated OCI balance, end of period | $0 | $0 | $0 | $0 | ||||
[1] | All of the forecasted transactions (future interest payments) were deemed probable of occurring; therefore, no cash flow hedges were discontinued and no amount was recognized in GenOn’s results of operations as a result of discontinued cash flow hedges. | |||||||
[2] | Amounts reclassified from accumulated OCI into income and amounts recognized in income from the ineffective portion of cash flow hedges are recorded in interest expense. | |||||||
[3] | The reversal of accumulated OCI as part of the sale of NRG Marsh Landing to NRG Yield LLC resulted in the recognition of additional paid in capital. |
Accounting_for_Derivative_Inst6
Accounting for Derivative Instruments and Hedging Activities (Details 5) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Unrealized mark-to-market results | ' | ' | ' | ' |
Reversal of previously recognized unrealized losses/(gains) on settled positions related to economic hedges | $59 | $73 | $210 | $270 |
Net unrealized gains/(losses) on open positions related to economic hedges | 57 | 18 | -112 | 56 |
Total unrealized mark-to-market gains/(losses) for economic hedging activities | -2 | -55 | -322 | -214 |
Reversal of previously recognized unrealized losses/(gains) on settled positions related to trading activity | 0 | 1 | 1 | 3 |
Net unrealized gains/(losses) on open positions related to trading activity | 0 | -1 | ' | 1 |
Total unrealized mark-to-market gains/(losses) for trading activity | 0 | -2 | -1 | -2 |
Total unrealized gains/(losses) | -2 | -57 | -323 | -216 |
Impact of derivative instruments to statement of operations | ' | ' | ' | ' |
Total impact to statement of operations | -2 | -57 | -323 | -216 |
Credit Risk Related Contingent Features | ' | ' | ' | ' |
Collateral required for contracts with adequate assurance clauses in net liability positions | 16 | ' | 16 | ' |
Collateral required for contracts with credit rating contingent features in net liability position | 1 | ' | 1 | ' |
Collateral due on net liability position that has not been called by a certain marginable agreement counterparty | 1 | ' | 1 | ' |
Gains (losses) included in operating revenues | ' | ' | ' | ' |
Unrealized mark-to-market results | ' | ' | ' | ' |
Total unrealized gains/(losses) | 3 | -48 | -341 | -238 |
Impact of derivative instruments to statement of operations | ' | ' | ' | ' |
Total impact to statement of operations | 3 | -48 | -341 | -238 |
Gains (losses) included in cost of operations | ' | ' | ' | ' |
Unrealized mark-to-market results | ' | ' | ' | ' |
Total unrealized gains/(losses) | -5 | -9 | 18 | 22 |
Impact of derivative instruments to statement of operations | ' | ' | ' | ' |
Total impact to statement of operations | -5 | -9 | 18 | 22 |
GenOn Americas Generation | ' | ' | ' | ' |
Unrealized mark-to-market results | ' | ' | ' | ' |
Reversal of previously recognized unrealized losses/(gains) on settled positions related to economic hedges | 65 | 69 | 201 | 218 |
Net unrealized gains/(losses) on open positions related to economic hedges | 30 | 11 | -55 | 37 |
Total unrealized mark-to-market gains/(losses) for economic hedging activities | -35 | -58 | -256 | -181 |
Reversal of previously recognized unrealized losses/(gains) on settled positions related to trading activity | 0 | 1 | 1 | 3 |
Net unrealized gains/(losses) on open positions related to trading activity | 0 | -1 | 0 | 1 |
Total unrealized mark-to-market gains/(losses) for trading activity | 0 | -2 | -1 | -2 |
Total unrealized gains/(losses) | -35 | -60 | -257 | -183 |
Impact of derivative instruments to statement of operations | ' | ' | ' | ' |
Total impact to statement of operations | -35 | -60 | -257 | -183 |
GenOn Americas Generation | Gains (losses) included in operating revenues | ' | ' | ' | ' |
Unrealized mark-to-market results | ' | ' | ' | ' |
Total unrealized gains/(losses) | -27 | -52 | -266 | -205 |
Impact of derivative instruments to statement of operations | ' | ' | ' | ' |
Total impact to statement of operations | -27 | -52 | -266 | -205 |
GenOn Americas Generation | Gains (losses) included in cost of operations | ' | ' | ' | ' |
Unrealized mark-to-market results | ' | ' | ' | ' |
Total unrealized gains/(losses) | -8 | -8 | 9 | 22 |
Impact of derivative instruments to statement of operations | ' | ' | ' | ' |
Total impact to statement of operations | -8 | -8 | 9 | 22 |
GenOn Mid-Atlantic | ' | ' | ' | ' |
Unrealized mark-to-market results | ' | ' | ' | ' |
Reversal of previously recognized unrealized losses/(gains) on settled positions related to economic hedges | 63 | 70 | 203 | 220 |
Net unrealized gains/(losses) on open positions related to economic hedges | 31 | 11 | -54 | 39 |
Total unrealized gains/(losses) | -32 | -59 | -257 | -181 |
Impact of derivative instruments to statement of operations | ' | ' | ' | ' |
Total impact to statement of operations | -32 | -59 | -257 | -181 |
GenOn Mid-Atlantic | Gains (losses) included in operating revenues | ' | ' | ' | ' |
Unrealized mark-to-market results | ' | ' | ' | ' |
Total unrealized gains/(losses) | -24 | -51 | -267 | -203 |
Impact of derivative instruments to statement of operations | ' | ' | ' | ' |
Total impact to statement of operations | -24 | -51 | -267 | -203 |
GenOn Mid-Atlantic | Gains (losses) included in cost of operations | ' | ' | ' | ' |
Unrealized mark-to-market results | ' | ' | ' | ' |
Total unrealized gains/(losses) | -8 | -8 | 10 | 22 |
Impact of derivative instruments to statement of operations | ' | ' | ' | ' |
Total impact to statement of operations | ($8) | ($8) | $10 | $22 |
Income_Taxes_Details
Income Taxes (Details) (USD $) | 3 Months Ended | 9 Months Ended | |||
In Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 |
Income tax provision | ' | ' | ' | ' | ' |
Income/(loss) before income taxes | $46 | $101 | $26 | ($69) | ' |
Income tax (benefit)/expense | 0 | 0 | 2 | -6 | ' |
Effective tax rate (as a percent) | 0.00% | 0.00% | 7.70% | 8.70% | ' |
Statutory tax rate (as a percent) | 35.00% | 35.00% | 35.00% | 35.00% | ' |
GenOn Americas Generation | ' | ' | ' | ' | ' |
Income tax provision | ' | ' | ' | ' | ' |
Income/(loss) before income taxes | 47 | 71 | 98 | 25 | ' |
Income tax (benefit)/expense | 0 | 0 | 0 | 0 | ' |
GenOn Americas Generation [Member] | ' | ' | ' | ' | ' |
Income tax provision | ' | ' | ' | ' | ' |
Income tax (benefit)/expense | 0 | 0 | 0 | 0 | ' |
GenOn Mid-Atlantic | ' | ' | ' | ' | ' |
Income tax provision | ' | ' | ' | ' | ' |
Income/(loss) before income taxes | 44 | 82 | 91 | 65 | ' |
Income tax (benefit)/expense | 0 | 0 | 0 | 0 | ' |
Pro Forma | GenOn Americas Generation [Member] | ' | ' | ' | ' | ' |
Income tax provision | ' | ' | ' | ' | ' |
Income tax (benefit)/expense | 0 | 0 | 0 | 0 | ' |
Pro Forma | GenOn Mid-Atlantic | ' | ' | ' | ' | ' |
Income tax provision | ' | ' | ' | ' | ' |
Income tax (benefit)/expense | 16 | 36 | 33 | 32 | ' |
Deferred income taxes | $106 | ' | $106 | ' | $141 |
Related_Party_Transactions_Det
Related Party Transactions (Details) (USD $) | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | 3 Months Ended | ||||||||||||
In Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2014 | Dec. 31, 2013 | Sep. 30, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 14, 2012 | Sep. 30, 2014 | Sep. 30, 2014 | Dec. 31, 2013 | Sep. 30, 2014 | Dec. 31, 2013 | Sep. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 |
GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | Direct cost of operations | Direct cost of operations | Direct cost of operations | Direct cost of operations | Intercompany Credit Agreement | Intercompany Credit Agreement | Intercompany Credit Agreement | Letter of Credit | Letter of Credit | Letter of Credit | Letter of Credit | Letter of Credit | Annual [Domain] | GenOn Americas Generation [Member] | GenOn North America [Domain] | |
NRG Energy | NRG Energy | GenOn | GenOn | GenOn Energy Holdings | GenOn Energy Holdings | NRG Energy | NRG Energy | GenOn | GenOn | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | Intercompany Credit Agreement | Intercompany Credit Agreement | Intercompany Credit Agreement | Intercompany Credit Agreement | Intercompany Credit Agreement | NRG Energy | GenOn North America [Domain] | GenOn Mid-Atlantic | ||||
GenOn | GenOn | GenOn | GenOn | NRG Energy | GenOn Americas Generation | GenOn Americas Generation | GenOn Mid-Atlantic | GenOn Mid-Atlantic | |||||||||||||||||
NRG Energy | NRG Energy | NRG Energy | NRG Energy | ||||||||||||||||||||||
Related Party Transaction | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Service Management Costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $193 | ' | ' |
Affiliate cost recorded in cost of operations | 20 | 63 | 20 | 64 | ' | ' | 17 | 52 | 17 | 53 | 33 | 37 | 99 | 62 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Maximum Borrowing Capacity | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500 | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Maximum Borrowing Capacity | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Letters of credit issued and oustanding on behalf of entity by affiliate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 151 | 258 | 219 | 349 | ' | ' | ' |
Term of Facility | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years | ' | ' | ' | ' | ' | ' | ' |
Debt instrument, interest rate over variable rate (as a percent) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.50% | ' | ' | ' | ' | ' | ' | ' |
Basis points added to interest under LIBOR rate loans (as a percent) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3.50% | ' | ' | ' | ' | ' | ' | ' |
Current note receivable from affiliate | ' | ' | ' | ' | 331 | 299 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Dividends | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $320 | $320 |
Related_Party_Transactions_Rel
Related Party Transactions Related Party Transactions (Details 2) (USD $) | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended |
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2014 |
GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Mid-Atlantic | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | |
GenOn | GenOn | NRG Energy | NRG Energy | Allocated cost of operations [Member] | Allocated cost of operations [Member] | Allocated cost of operations [Member] | Allocated cost of operations [Member] | Allocated Selling, General and Administrative [Member] | Allocated Selling, General and Administrative [Member] | Allocated Selling, General and Administrative [Member] | Allocated Selling, General and Administrative [Member] | GenOn | GenOn | NRG Energy | NRG Energy | Allocated cost of operations [Member] | Allocated cost of operations [Member] | Allocated cost of operations [Member] | Allocated cost of operations [Member] | Allocated Selling, General and Administrative [Member] | Allocated Selling, General and Administrative [Member] | Allocated Selling, General and Administrative [Member] | Allocated Selling, General and Administrative [Member] | |
GenOn | GenOn | NRG Energy | NRG Energy | GenOn | GenOn | NRG Energy | NRG Energy | GenOn | GenOn | NRG Energy | NRG Energy | GenOn | GenOn | NRG Energy | NRG Energy | |||||||||
Related Party Transaction | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Related Party Transaction, Expenses from Transactions with Related Party | $17 | $53 | $17 | $52 | $2 | $5 | $0 | $0 | ' | ' | ' | ' | $20 | $64 | $20 | $63 | $2 | $7 | $0 | $1 | ' | ' | ' | ' |
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party | ' | ' | ' | ' | ' | ' | ' | ' | $15 | $48 | $17 | $52 | ' | ' | ' | ' | ' | ' | ' | ' | $18 | $57 | $20 | $62 |
Commitments_and_Contingencies_
Commitments and Contingencies (Details) (USD $) | 12 Months Ended | ||||
Dec. 31, 2008 | Dec. 31, 2008 | Mar. 31, 2014 | Dec. 14, 2012 | Dec. 02, 2010 | |
Cheswick Monarch Mine NOV | MDE v. GenOn Chalk Point and GenOn Mid-Atlantic | Chapter Eleven Proceedings | Chapter Eleven Proceedings | Chapter Eleven Proceedings | |
Environmental Matters | GenOn Mid-Atlantic | GenOn Americas Generation | GenOn Americas Generation | GenOn Americas Generation | |
Environmental Matters | Bankruptcy | Bankruptcy | Bankruptcy | ||
Maryland Department of the Environment v. GenOn Chalk Point and GenOn Mid-Atlantic | ' | ' | ' | ' | ' |
Loss Contingency, Damages Sought, Value | $200,000 | $100,000 | ' | ' | ' |
Chapter Eleven Proceedings | ' | ' | ' | ' | ' |
GenOn Energy Holdings common stock shares reserved for unresolved claims | ' | ' | 461,000 | ' | ' |
Number of reserved shares for disputed Chapter 11 claims converted into reserved of GenOn common stock | ' | ' | ' | ' | 1,300,000 |
Number of reserved shares for disputed Chapter 11 claims converted into reserved of NRG common stock | ' | ' | ' | 159,000 | ' |
Environmental_Matters_Details
Environmental Matters (Details) (USD $) | Sep. 30, 2014 |
In Millions, unless otherwise specified | |
Environmental Matters Disclosure | ' |
Estimated environmental capital expenditures from 2013 through 2017 | $109 |
GenOn Americas Generation | ' |
Environmental Matters Disclosure | ' |
Estimated environmental capital expenditures from 2013 through 2017 | 15 |
GenOn Mid-Atlantic | ' |
Environmental Matters Disclosure | ' |
Estimated environmental capital expenditures from 2013 through 2017 | $10 |